<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="lead">
            <roleset id="lead.01" name="resulted&#x0A;" wordnet="3">
                <roles>
                    <role n="0" descr="factors&#x0A;" />
                    <role n="2" descr="result&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A0, in turn, is able to lead to synergistic activation of ANA and other target MEF2 promoters regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergistic activation of ANA and other target MEF2 promoters</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A0, in turn, led synergic activation of the ANA and other MEF2 target promoters to an activity independent of the MEF2 DNA binding activity.</text>
                    <arg n="1">synergic activation of the ANA and other MEF2 target promoters</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Crl stimulates sigma (S) activity leads to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Display of the SNU246 gene in yeast was lethal and led to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 is able to lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction nCaRE-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">nCaRE</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>In this homologous part of genes, GBP lacks an exon due to a point mutation at the application site of the third intron, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Loss of TreR function led derepression of treB to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>The mutation of cut at 5 ends of the intron 5 can lead to the abnormal exon 5 and portion of exon 6 appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>The mutations identified include: with two exchanges of frames and a mutation at the fitting site leading to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>These results suggest that the different amino acid terminals may lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>This basic pair G:C is also the strongest determinant in sequence selection experience that leads to BRE identification (Lagrange et al., 1998).</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>This data suggests that phosphorylation of the MuSK site NPXY has led to capture of a protein containing phosphorosine binding domains that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>This data suggests that phosphorylation of the NPXY site of MuSK led to recovery of a domain protein bound to phosphotyrosine working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>This patient DNA contains a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele which leads to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>This was caused by a punctual mutation (GTC----ATC) in codon 383 leading to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>We also studied in detail a complex coupling site mutation, 3332dupl8bp, which was found to lead to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>We also study in detail a complex mutation of the coupling site, 3332dupl8bp, which leads to an abnormal JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>a closer analysis of the putative signal transduction pathway that modulates HtrA transcription led to the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase was led by Crl stimulates sigma activity (S).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>an increase in the transcription rate of a subset of rpoS genes in the stationary phase was led to Crl stimulates sigma activity (S).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase is led by Crl stimulates sigma activity (S).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>disorganization of the SNU246 gene in the yeast was lethal and led to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% expression decrease when cells are grown in a rich environment.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% decrease in expression when the cells were cultured in a rich medium.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite will lead to a 45% decrease in expression when cells are grown in a rich environment.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>growth of scherichia coli in the presence of nitrate or nitrite was able to lead to a 45% drop in expression when the cells were grown in rich environments.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>the 5-end mutation of the intron 5 may led to abnormal portion in exon 5 and exon 6 and cause unstable and abnormal ALD proteins; lignocceryl CoA ligase does not carry very long-chain fatty acids (VLCFA) to the peroxide and does not work normally; consequently, the beta-defective oxidation of VLCFA in the peroxide may result in a</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>the closest test to the putative signal transduction pathway that modulates the htrA transcription will lead to identification of two new genes.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>the mutation of the splice at 5 ends of the intron 5 has led to the abnormal splice in exon 5 and exon 6 appears to be one of the causes of recessive adreoleukodrophite linked to X.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>the mutation of the splice at 5 ends of the intron 5 led to the splice in exon 5 and exon 6 appears to be one of the causes of recessive adreoleukodropia linked to X.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>this can lead to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>this mutation at 5 ends of the intron 5 can led to abnormal portion in exon 5 and exon 6 and cause unstable and abnormal ALD proteins; lignocceryl CoA ligase cannot transport very long-chain fatty acids (VLCFA) to the peroxysoma and cannot function normally; consequently, the defective beta oxidation of VLCFA in the peroxysoma can result in an accumulation of VLCFAS in the central nervous system, adrenal glands and blood.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A0 (i.e., in turn, led to synergic activation of the ANA and other MEF2 target promoters regardless of the binding activity of meF2.</text>
                    <arg n="1">synergic activation of the ANA and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A0, in turn, is able to lead to synergic activation of the ANF and other MEF2 target promoters regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>A0, in turn, is able to lead to synergistic activation of ANA and other target promoters of MEF2 regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>A0, in turn, is capable of leading to synergistic activation of ANA and other target MEF2 promoters regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergistic activation of ANA and other target MEF2 promoters</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A0, in turn, led synergic activation of the ANF and other MEF2 target promoters to an activity independent of the MEF2 DNA binding activity.</text>
                    <arg n="1">synergic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A0, in turn, led synergistic activation of ANA and other target MEF2 promoters to an activity independent of the MEF2 DNA binding activity.</text>
                    <arg n="1">synergistic activation of ANA and other target MEF2 promoters</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>A0, in turn, led to synergistic activation of ANA and other target MEF2 promoters regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergistic activation of ANA and other target MEF2 promoters</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>A0, in turn, will lead to synergic activation of the ANA and other MEF2 target promoters regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergic activation of the ANA and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>BRE identification is led to sequence selection experience.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>C2+e-mediated transcriptional supression was led to nCaRE.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a 40 to 50-fold synergistic activation of the ANA promoter (figuration 3A).</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Crl stimulates sigma (S) activity can lead to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Crl stimulates sigma (S) activity leading to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Crl stimulates sigma (S) activity led to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase (figuration 3A).</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Crl stimulates sigma (S) activity led to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase (figure 3A).</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Crl stimulates sigma (S) activity led to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Crl stimulates sigma activity (S) can lead to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase (figuration 3A).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Crl stimulates sigma activity (S) is able to lead to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Crl stimulates sigma activity (S) leading to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Crl stimulates sigma activity (S) leading to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of rpoS genes in the stationary phase coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Crl stimulates sigma activity (S) led an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of rpoS genes in the stationary phase, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Crl stimulates sigma activity (S) may lead to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase (figure 3A).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Crl stimulates sigma activity (S) may lead to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Crl stimulates sigma activity (S) may lead to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Crl stimulates sigma activity (S) will lead to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Crl stimulates sigma activity (S), in turn, is leading to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>DNA (nCaRE)-ref1 can lead to C2+e transcriptional deletion (figuration 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>DNA (nCaRE)-ref1 can lead to C2+e transcriptional deletion, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>DNA (nCaRE)-ref1 has led in C2+ and transcriptional deletion, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>DNA (nCaRE)-ref1 is leading to C2+ and transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>DNA (nCaRE)-ref1 leading to C2+e transcriptional deletion, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>DNA (nCaRE)-ref1 leading to C2+e transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>DNA (nCaRE)-ref1 led to C2+e transcriptional deletion (figuration 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>DNA (nCaRE)-ref1 led to C2+e transcriptional deletion (figure 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>DNA (nCaRE)-ref1 led to C2+e transcriptional deletion, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>DNA (nCaRE)-ref1 may lead to C2+ and transcriptional deletion (figure 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>DNA (nCaRE)-ref1 will lead to C2+e transcriptional deletion coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 can lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 has led in a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 may lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 may lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C or MEF2D can lead to a synergistic activation of 40 to 50 folds of the promoter ANA.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C or MEF2D is able to lead a synergistic activation of 40 to 50 folds of the promoter ANA (picture 3A).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C or MEF2D leading to a synergistic activation of 40 to 50 folds of the promoter ANA, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D can lead to a synergistic activation of 40 to 50 times that of the ANA promoter, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D is leading to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D leading to a synergistic activation of 40 to 50 times that of the ANA promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D leading to a synergistic activation of 40 to 50 times that of the ANA promoter, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D leads to a synergistic activation of 40 to 50 times that of the ANA promoter coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D led to a synergistic activation of 40 to 50 times that of the ANA promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D may lead to a synergistic activation of 40 to 50 times that of the ANA promoter (figure 3A).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D may lead to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D can lead to a 40 to 50-fold synergistic activation of the aF promoter, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D has led in a 40 to 50-fold synergistic activation of the aF promoter.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D leading to a 40 to 50-fold synergistic activation of the aF promoter, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D leads to a 40 to 50-fold synergistic activation of the aF promoter coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D led a 40 to 50-fold synergistic activation of the aF promoter to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D led to a 40 to 50-fold synergistic activation of the aF promoter (figuration 3A).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D led to a 40 to 50-fold synergistic activation of the aF promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D may lead to a 40 to 50-fold synergistic activation of the aF promoter coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>GM2 can lead to a neurological disease, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>GM2 genetic deficiency, in turn, is leading to a neurological disorder regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>GM2 leads to a neurological disease coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>GM2 was able to lead to a neurological disease when the cells were grown in rich environments.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a point mutation at the pulse site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction a C---A transversion following the helix of the last intron of the ERCC-3 allele-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">a C---A transversion following the helix of the last intron of the ERCC-3 allele</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction a C---A transversion following the helix of the last intron of the ERCC-3 allele-ref1) was able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">a C---A transversion following the helix of the last intron of the ERCC-3 allele</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D leads to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction This leads to a wide diversity of nebulin and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction This leads to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele leads to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a point mutation at the application site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction mutation of cut at 5 ends of the intron 5 leads to abnormal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction phosphorylation of MuSK NPXY site leads to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction phosphorylation of the MuSK site NPXY leads to capture of a phosphorosine binding protein.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction phosphorylation of the MuSK site NPXY leads to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction phosphorylation of the NPXY site of MuSK leads to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction sequence selection experience leads to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction the closest test to the transduction pathway of putative signals that modulates the transcription htrA leads to identification of two new genes.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction this leads to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction two changes in the picture and one mutation at the fitting site leads to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction Crl stimulates sigma activity (S)-ref1 is able to lead to transcriptional suppression an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction This-ref1 is able to lead to transcriptional suppression a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction genetic deficiency of the GM2 activator-ref1 is able to lead to transcriptional suppression a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction genetic deficiency of the GM2 activator-ref1 is able to lead to transcriptional suppression a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction mutation of cut at 5 ends of the intron 5-ref1 is able to lead to transcriptional suppression abnormal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction phosphorylation of the MuSK site NPXY-ref1 is able to lead to transcriptional suppression capture of a phosphorosine binding protein.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction phosphorylation of the NPXY MuSK site-ref1 is able to lead to transcriptional suppression recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction phosphorylation of the NPXY site of MuSK-ref1 is able to lead to transcriptional suppression recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction phosphorylation of the site NPXY MuSK-ref1 is able to lead to transcriptional suppression recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction the sequence selection experiment-ref1 is able to lead to transcriptional suppression the identification of BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>In this homologous part of genes, GBP lacks an exon due to Crl stimulates sigma (S) activity, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>In this homologous part of genes, GBP lacks an exon due to Crl stimulates sigma activity (S), which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>In this homologous part of genes, GBP lacks an exon due to a C--A transversion after the last intron sternalization aceptors of the ERCC-3, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>In this homologous part of genes, GBP lacks an exon due to a closer examination of the transduction pathway of putative signals that modulates the transcription htrA, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>In this homologous part of genes, GBP lacks an exon due to a point mutation at the pulse site of the third intron, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>In this homologous part of genes, GBP lacks an exon due to closer to the transduction pathway of the putative signal that modulates the htrA transcription, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>In this homologous part of genes, GBP lacks an exon due to cut switch at 5 ends of the intron 5, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>In this homologous part of genes, GBP lacks an exon due to mutation of cutting at 5 ends of the intron 5, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>In this homologous part of genes, GBP lacks an exon due to phosphorylation of the MuSK site NPXY, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>In this homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>In this homologous part of genes, GBP lacks an exon due to two changes in the picture and one mutation at the fitting site, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>In this homologous part of genes, GBP lacks an exon due to with two exchanges of frames and a mutation at the fitting site, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>In this homologous part of genes, GPB does not have an exon due to DNA (nCaRE)-ref1, which inactivates the pulse event of the 5th and may lead to C2+ and transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>In this homologous part of genes, GPB does not have an exon due to a mutation point (GTC---ATC) in codon 383, which inactivates the pulse event of the 5th and may lead to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>In this homologous part of genes, GPB does not have an exon due to closer to the transduction pathway of the putative signal that modulates the htrA transcription, which inactivates the pulse event of the 5th and may lead to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>In this homologous part of genes, GPB does not have an exon due to mutation of cutting at 5 ends of the intron 5, which inactivates the pulse event of the 5th and may lead to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>In this homologous part of genes, GPB does not have an exon due to phosphorylation of MuSK NPXY site, which inactivates the pulse event of the 5th and may lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>In this homologous part of genes, GPB does not have an exon due to phosphorylation of the NPXY MuSK site, which inactivates the pulse event of the 5th and may lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>In this homologous part of genes, GPB does not have an exon due to sequence selection experience, which inactivates the pulse event of the 5th and may lead to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>In this homologous part of the genes, GBP does not have an exon due to This, which inactivates the pulse segmentation event and leads to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>In this homologous part of the genes, GBP does not have an exon due to a C--A transversion after the last intron sternalization aceptors of the ERCC-3, which inactivates the pulse segmentation event and leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>In this homologous part of the genes, GBP does not have an exon due to a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription, which inactivates the pulse segmentation event and leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>In this homologous part of the genes, GBP does not have an exon due to a punctual mutation (GTC----ATC) in codon 383, which inactivates the pulse segmentation event and leads to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>In this homologous part of the genes, GBP does not have an exon due to a punctual mutation (GTC----ATC) in codon 383, which inactivates the pulse segmentation event and leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>In this homologous part of the genes, GBP does not have an exon due to closer to the transduction pathway of the putative signal that modulates htrA transcription, which inactivates the pulse segmentation event and leads to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>In this homologous part of the genes, GBP does not have an exon due to genetic deficiency of the GM2 activator, which inactivates the pulse segmentation event and leads to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>In this homologous part of the genes, GBP does not have an exon due to mutation of cutting at 5 ends of the intron 5, which inactivates the pulse segmentation event and leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>In this homologous part of the genes, GBP does not have an exon due to phosphorylation of the MuSK site NPXY, which inactivates the pulse segmentation event and leads to capture of a phosphorosine binding protein.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>In this homologous part of the genes, GBP does not have an exon due to phosphorylation of the NPXY MuSK site, which inactivates the pulse segmentation event and leads to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>Loss of TreR function can lead to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>Loss of TreR function has led in derepression of treB, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>Loss of TreR function leading to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>Loss of TreR function led to derepression of treB (figure 3A).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>Loss of TreR function led to derepression of treB, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Loss of TreR function may lead to derepression of treB (figure 3A).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>The Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D led to the a 40 to 50-fold synergistic activation of the ANA promoter appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>The Crl stimulates sigma (S) activity leads to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>The Crl stimulates sigma (S) activity will lead to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>The Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>The Crl stimulates sigma activity (S) led to the an increase in the transcription rate of a subset of rpoS genes in the stationary phase appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>The DNA (nCaRE)-ref1 can lead to the C2+ and transcriptional deletion appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>The G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>The G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 led to the a substitution of a positive load in a highly conserved transmembrane domain (R496S) appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>The GATA-4 co-transfection with MEF2A, MEF2C or MEF2D led to the a synergistic activation of 40 to 50 folds of the promoter ANA appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>The GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D can lead to the a synergistic activation of 40 to 50 times that of the ANA promoter appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>The GATA-4 cotransformation with MEF2A, MEF2C or MEF2D led to a 40 to 50-fold synergistic activation of the aF promoter.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>The GATA-4 cotransformation with MEF2A, MEF2C or MEF2D led to the a 40 to 50-fold synergistic activation of the aF promoter appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>The GM2 will lead to a neurological disease.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>The Loss of TreR function leads to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>The Loss of TreR function led to the derepression of treB appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>The Loss of TreR function will lead to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>The This can lead to the a wide diversity of nebulin and nebule isoforms appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>The This can lead to the a wide diversity of nebulins and nebule isoforms appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>The This leads to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>The This will lead to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>The a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele led to the an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>The a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele led to the an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>The a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele can lead to the an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>The a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>The a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele will lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>The a C--A transversion after the last intron sternalization aceptors of the ERCC-3 leads to the an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>The a C--A transversion after the last intron sternalization aceptors of the ERCC-3 will lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>The a closer analysis of the putative signal transduction pathway that modulates HtrA transcription led to the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>The a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>The a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription will lead to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>The a closer examination of the transduction pathway of putative signals that modulates the transcription htrA led to the the identification of two new genes appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>The a closer examination of the transduction pathway of putative signals that modulates the transcription htrA led to the the identification of two new genes appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>The a closer examination of the transfer pathway of putative signals that modulates the transcription htrA led to the the identification of two new genes appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>The a point mutation (GTC---ATC) in codon 383 can lead to the conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>The a point mutation (GTC---ATC) in codon 383 led to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>The a point mutation (GTC---ATC) in codon 383 led to the conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>The a point mutation at the application site of the third intron led to the ligation of the second to the fourth exon appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>The a point mutation at the application site of the third intron led to the ligation of the second to the fourth exon appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>The a point mutation at the pulse site of the third intron can lead to the ligation of the second to the fourth intron appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>The a point mutation at the pulse site of the third intron led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>The a point mutation at the pulse site of the third intron led to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>The a point mutation at the pulse site of the third intron led to the ligation of the second to the fourth exon appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>The closer to the transduction pathway of the putative signal that modulates the htrA transcription led to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>The closer to the transduction pathway of the putative signal that modulates the htrA transcription led to the the identification of two new genes appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>The closer to the transduction pathway of the putative signal that modulates the htrA transcription will lead to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>The cut switch at 5 ends of the intron 5 leads to abnormal exon 5 and exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>The cut switch at 5 ends of the intron 5 leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>The cut switch at 5 ends of the intron 5 leads to the abnormal exon 5 and exon 6 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>The genetic deficiency of the GM2 activator led to the a neurological disease appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>The growth of scherichia coli in the presence of nitrate or nitrite leads to a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>The mutation of cut at 5 ends of the intron 5 led to the abnormal exon 5 and portion of exon 6 appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>The mutation of cutting at 5 ends of the intron 5 led to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>The mutation of cutting at 5 ends of the intron 5 led to the normal exon 5 and portion of exon 6 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>The mutations identified include: GATA-4 co-transfection with MEF2A, MEF2C or MEF2D that led to a synergistic activation of 40 to 50 folds of the promoter ANA, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>The mutations identified include: GATA-4 cotransformation with MEF2A, MEF2C or MEF2D that led to a 40 to 50-fold synergistic activation of the aF promoter, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>The mutations identified include: This that led to a wide diversity of nebulin and nebule isoforms, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>The mutations identified include: This that led to a wide diversity of nebulin and nebule isoforms, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>The mutations identified include: a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele leading to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>The mutations identified include: a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele that led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>The mutations identified include: a C--A transversion after the last intron sternalization aceptors of the ERCC-3 that led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>The mutations identified include: a point mutation (GTC---ATC) in codon 383 that led to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>The mutations identified include: a point mutation at the pulse site of the third intron leading to ligation of the second to the fourth intron, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>The mutations identified include: a point mutation at the pulse site of the third intron that led to ligation of the second to the fourth exon, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>The mutations identified include: a punctual mutation (GTC----ATC) in codon 383 that led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>The mutations identified include: closer to the transduction pathway of the putative signal that modulates the htrA transcription that led to the identification of two new genes, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>The mutations identified include: cut switch at 5 ends of the intron 5 leading to normal exon 5 and portion of exon 6, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>The mutations identified include: genetic deficiency of the GM2 activator that led to a neurological disorder, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>The mutations identified include: growth of scherichia coli in the presence of nitrate or nitrite leading to a 45% drop in expression, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>The mutations identified include: growth of scherichia coli in the presence of nitrate or nitrite that led to a 45% drop in expression, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>The mutations identified include: mutation of cut at 5 ends of the intron 5 leading to abnormal exon 5 and portion of exon 6, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>The mutations identified include: phosphorylation of the MuSK site NPXY leading to capture of a phosphorosine binding protein, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>The mutations identified include: phosphorylation of the MuSK site NPXY that led to capture of a protein containing phosphorosine binding domains, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>The mutations identified include: phosphorylation of the NPXY MuSK site that led to recruitment of a domain protein bound to phosphotyrosine, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>The mutations identified include: phosphorylation of the NPXY site of MuSK that led to recovery of a domain protein bound to phosphotyrosine, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>The mutations identified include: phosphorylation of the NPXY site of MuSK that led to recovery of a domain protein bound to phosphotyrosine, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>The mutations identified include: phosphorylation of the site NPXY MuSK leading to recovery of a domain protein bound to phosphotyrosine, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>The mutations identified include: sequence selection experience leading to BRE identification, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>The mutations identified include: the closest test to the transduction pathway of putative signals that modulates the transcription htrA that led to identification of two new genes, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>The mutations identified include: this that led to a substantial diversity of isoforms of nebulin and nebulae, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>The mutations identified include: with two exchanges of frames and a mutation at the fitting site leading to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>The mutations identified include: with two exchanges of frames and a mutation at the fitting site that led to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>The mutations identified include: with two exchanges of frames and a mutation at the fitting site that led to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>The phosphorylation of the MuSK site NPXY led to capture of a phosphorosine binding protein.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>The phosphorylation of the MuSK site NPXY led to the recovery of a protein bound to phosphorosine appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>The phosphorylation of the NPXY MuSK site led to the recruitment of a domain protein bound to phosphotyrosine appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>The phosphorylation of the NPXY site of MuSK will lead to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>The phosphorylation of the site NPXY MuSK can lead to the recovery of a domain protein bound to phosphorosine appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>The phosphorylation of the site NPXY MuSK leads to the recovery of a domain protein bound to phosphorosine appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>The sequence selection experience will lead to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>The the closest test to the putative signal transduction pathway that modulates the htrA transcription led to the identification of two new genes appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>The the closest test to the transduction pathway of putative signals that modulates the transcription htrA led to the identification of two new genes appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>The this can lead to the a substantial diversity of isoforms of nebulin and nebulette appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>The this leads to the a substantial diversity of isoforms of nebulin and nebulae appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, may lead to two changes in the picture and one mutation at the ear site.</text>
                    <arg n="0">two changes in the picture and one mutation at the ear site</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to two changes in the picture and one mutation at the ear site.</text>
                    <arg n="0">two changes in the picture and one mutation at the ear site</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to the loss of OmpF.</text>
                    <arg n="0">the loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to the loss of OmpF.</text>
                    <arg n="0">the loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>The with two exchanges of frames and a mutation at the fitting site leads to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>The with two exchanges of frames and a mutation at the fitting site led to the elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>The with two exchanges of frames and a mutation at the fitting site led to the oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>The with two exchanges of frames and a mutation at the fitting site will lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>These data suggest that Crl stimulates sigma (S) activity led to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>These data suggest that Crl stimulates sigma (S) activity may lead to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>These data suggest that GATA-4 co-transfection with MEF2A, MEF2C or MEF2D may lead to a synergistic activation of 40 to 50 folds of the promoter ANA that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>These data suggest that GATA-4 cotransformation with MEF2A, MEF2C or MEF2D was able to lead to a 40 to 50-fold synergistic activation of the aF promoter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>These data suggest that This led to synergistic activation of ANA and other target promoters of MEF2 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>These data suggest that This was able to lead to a wide diversity of nebulins and nebule isoforms that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>These data suggest that a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele was able to lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>These data suggest that a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele was able to lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>These data suggest that a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription led to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>These data suggest that a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription was able to lead to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>These data suggest that a closer examination of the transfer pathway of putative signals that modulates the transcription htrA was able to lead to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>These data suggest that a mutation point (GTC---ATC) in codon 383 may lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>These data suggest that a point mutation at the pulse site of the third intron was able to lead to ligation of the second to the fourth exon that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>These data suggest that a punctual mutation (GTC----ATC) in codon 383 led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>These data suggest that closer to the transduction pathway of the putative signal that modulates the htrA transcription led to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>These data suggest that genetic deficiency of the GM2 activator may lead to a neurological disorder that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>These data suggest that nCaRE led to C2+e-mediated transcriptional supression that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>These data suggest that phosphorylation of the MuSK site NPXY may lead to capture of a phosphorosine binding protein that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>These data suggest that phosphorylation of the NPXY site of MuSK was able to lead to recovery of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>These data suggest that phosphorylation of the site NPXY MuSK may lead to recovery of a domain protein bound to phosphorosine that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>These data suggest that sequence selection experience led to BRE identification that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>These data suggest that the sequence selection experiment may lead to the identification of BRE that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>These data suggest that the sequence selection experiment was able to lead to the identification of BRE that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>These data suggest that this led to a substantial diversity of isoforms of nebulin and nebulae that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>These data suggest that two changes in the picture and one mutation at the fitting site led to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>These data suggest that with two exchanges of frames and a mutation at the fitting site may lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>These data suggest that with two exchanges of frames and a mutation at the fitting site may lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>This DNA of patients contains G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 allele that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>This DNA of patients contains GATA-4 cotransformation with MEF2A, MEF2C or MEF2D that led to a 40 to 50-fold synergistic activation of the aF promoter.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>This DNA of patients contains Loss of TreR function that led to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>This DNA of patients contains This allele that can lead to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>This DNA of patients contains a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele that led to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>This DNA of patients contains a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription that led to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>This DNA of patients contains cut switch at 5 ends of the intron 5 allele that can lead to abnormal exon 5 and exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>This DNA of patients contains genetic deficiency of the GM2 activator allele that can lead to a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>This DNA of patients contains nCaRE that led to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>This DNA of patients contains phosphorylation of the MuSK site NPXY allele that can lead to capture of a phosphorosine binding protein.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>This DNA of patients contains phosphorylation of the MuSK site NPXY allele that can lead to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>This DNA of patients contains phosphorylation of the MuSK site NPXY allele that can lead to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>This DNA of patients contains phosphorylation of the MuSK site NPXY that led to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>This DNA of patients contains phosphorylation of the site NPXY MuSK that led to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>This DNA of patients contains the closest test to the putative signal transduction pathway that modulates the htrA transcription that led to identification of two new genes.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>This DNA of patients contains this that led to a substantial diversity of isoforms of nebulin and nebulette.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>This DNA of patients contains two changes in the picture and one mutation at the fitting site that led to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>This base pair G:C is also the strongest determinant in Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of rpoS genes in the stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>This base pair G:C is also the strongest determinant in Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>This base pair G:C is also the strongest determinant in Crl stimulates sigma activity (S) that led to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 that led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>This base pair G:C is also the strongest determinant in GM2 genetic deficiency that has led to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>This base pair G:C is also the strongest determinant in GM2 leads to a neurological disease (Lagrange et al., 1998).</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>This base pair G:C is also the strongest determinant in Loss of TreR function leads to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>This base pair G:C is also the strongest determinant in This that has led to synergistic activation of ANA and other target promoters of MEF2 (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>This base pair G:C is also the strongest determinant in This that led to a wide diversity of nebulae and nebulae (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>This base pair G:C is also the strongest determinant in This that led to synergistic activation of ANA and other target promoters of MEF2 (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>This base pair G:C is also the strongest determinant in a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C (Lagrange et al., 1998).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>This base pair G:C is also the strongest determinant in a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leading to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C (Lagrange et al., 1998).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>This base pair G:C is also the strongest determinant in a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C (Lagrange et al., 1998).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>This base pair G:C is also the strongest determinant in a C--A transversion after the last intron sternalization aceptors of the ERCC-3 leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid (Lagrange et al., 1998).</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>This base pair G:C is also the strongest determinant in a C--A transversion after the last intron sternalization aceptors of the ERCC-3 that led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid (Lagrange et al., 1998).</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>This base pair G:C is also the strongest determinant in a closer analysis of the putative signal transduction pathway that modulates HtrA transcription that has led to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>This base pair G:C is also the strongest determinant in a closer analysis of the putative signal transduction pathway that modulates HtrA transcription that led to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>This base pair G:C is also the strongest determinant in a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription leads to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>This base pair G:C is also the strongest determinant in a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription that led to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>This base pair G:C is also the strongest determinant in a closer examination of the transduction pathway of putative signals that modulates the transcription htrA leading to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>This base pair G:C is also the strongest determinant in a closer examination of the transduction pathway of putative signals that modulates the transcription htrA leads to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>This base pair G:C is also the strongest determinant in a closer examination of the transfer pathway of putative signals that modulates the transcription htrA leading to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>This base pair G:C is also the strongest determinant in a mutation point (GTC---ATC) in codon 383 leads to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop (Lagrange et al., 1998).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>This base pair G:C is also the strongest determinant in a point mutation (GTC---ATC) in codon 383 leads to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>This base pair G:C is also the strongest determinant in a point mutation (GTC---ATC) in codon 383 that led to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>This base pair G:C is also the strongest determinant in a point mutation at the pulse site of the third intron that led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>This base pair G:C is also the strongest determinant in a punctual mutation (GTC----ATC) in codon 383 leading to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>This base pair G:C is also the strongest determinant in a punctual mutation (GTC----ATC) in codon 383 that led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>This base pair G:C is also the strongest determinant in a punctual mutation (GTC----ATC) in codon 383 that led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>This base pair G:C is also the strongest determinant in closer to the transduction pathway of the putative signal that modulates the htrA transcription leading to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>This base pair G:C is also the strongest determinant in cut switch at 5 ends of the intron 5 leading to abnormal exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>This base pair G:C is also the strongest determinant in cut switch at 5 ends of the intron 5 that led to abnormal exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>This base pair G:C is also the strongest determinant in genetic deficiency of the GM2 activator leading to a neurological disease (Lagrange et al., 1998).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>This base pair G:C is also the strongest determinant in genetic deficiency of the GM2 activator that has led to a neurological disease (Lagrange et al., 1998).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>This base pair G:C is also the strongest determinant in growth of scherichia coli in the presence of nitrate or nitrite leading to a 45% drop in expression (Lagrange et al., 1998).</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>This base pair G:C is also the strongest determinant in mutation of cut at 5 ends of the intron 5 leads to abnormal exon 5 and portion of exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>This base pair G:C is also the strongest determinant in phosphorylation of the MuSK site NPXY leading to capture of a protein containing phosphorosine binding domains (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>This base pair G:C is also the strongest determinant in phosphorylation of the MuSK site NPXY that led to capture of a protein containing phosphorosine binding domains (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>This base pair G:C is also the strongest determinant in phosphorylation of the NPXY MuSK site leading to recruitment of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>This base pair G:C is also the strongest determinant in phosphorylation of the NPXY MuSK site leads to recruitment of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>This base pair G:C is also the strongest determinant in phosphorylation of the NPXY site of MuSK leads to recovery of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>This base pair G:C is also the strongest determinant in phosphorylation of the site NPXY MuSK leads to recovery of a domain protein bound to phosphorosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>This base pair G:C is also the strongest determinant in sequence selection experience leads to BRE identification (Lagrange et al., 1998).</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>This base pair G:C is also the strongest determinant in sequence selection experience that led to BRE identification (Lagrange et al., 1998).</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>This base pair G:C is also the strongest determinant in the closest test to the transduction pathway of putative signals that modulates the transcription htrA that has led to identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>This base pair G:C is also the strongest determinant in two changes in the picture and one mutation at the fitting site that led to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction (Lagrange et al., 1998).</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>This base pair G:C is also the strongest determinant in with two exchanges of frames and a mutation at the fitting site leading to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction (Lagrange et al., 1998).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>This basic pair G:C is also the strongest determinant in Crl stimulates sigma activity (S) that led to an increase in the transcription rate of a subset of rpoS genes in the stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>This basic pair G:C is also the strongest determinant in G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 that leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>This basic pair G:C is also the strongest determinant in G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 that led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>This basic pair G:C is also the strongest determinant in GATA-4 cotransformation with MEF2A, MEF2C or MEF2D that leads to a 40 to 50-fold synergistic activation of the aF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>This basic pair G:C is also the strongest determinant in GM2 genetic deficiency leading to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>This basic pair G:C is also the strongest determinant in Loss of TreR function that leads to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>This basic pair G:C is also the strongest determinant in Loss of TreR function that led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>This basic pair G:C is also the strongest determinant in This leading to synergistic activation of ANA and other target promoters of MEF2 (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>This basic pair G:C is also the strongest determinant in This that led to a wide diversity of nebulae and nebulae (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>This basic pair G:C is also the strongest determinant in This that led to a wide diversity of nebulins and nebule isoforms (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>This basic pair G:C is also the strongest determinant in a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele that led to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>This basic pair G:C is also the strongest determinant in a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leading to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C (Lagrange et al., 1998).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>This basic pair G:C is also the strongest determinant in a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele that leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C (Lagrange et al., 1998).</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>This basic pair G:C is also the strongest determinant in a C--A transversion after the last intron sternalization aceptors of the ERCC-3 leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid (Lagrange et al., 1998).</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>This basic pair G:C is also the strongest determinant in a mutation point (GTC---ATC) in codon 383 leading to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop (Lagrange et al., 1998).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>This basic pair G:C is also the strongest determinant in a mutation point (GTC---ATC) in codon 383 that led to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop (Lagrange et al., 1998).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>This basic pair G:C is also the strongest determinant in a point mutation at the pulse site of the third intron leading to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>This basic pair G:C is also the strongest determinant in a point mutation at the pulse site of the third intron that led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>This basic pair G:C is also the strongest determinant in genetic deficiency of the GM2 activator leading to a neurological disease (Lagrange et al., 1998).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>This basic pair G:C is also the strongest determinant in mutation of cut at 5 ends of the intron 5 that leads to abnormal exon 5 and portion of exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>This basic pair G:C is also the strongest determinant in mutation of cutting at 5 ends of the intron 5 that leads to normal exon 5 and portion of exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>This basic pair G:C is also the strongest determinant in phosphorylation of MuSK NPXY site that leads to recruitment of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>This basic pair G:C is also the strongest determinant in phosphorylation of the MuSK site NPXY leading to recovery of a protein bound to phosphorosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>This basic pair G:C is also the strongest determinant in the closest test to the putative signal transduction pathway that modulates the htrA transcription that led to identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>This basic pair G:C is also the strongest determinant in the closest test to the transduction pathway of putative signals that modulates the transcription htrA that leads to identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>This basic pair G:C is also the strongest determinant in the closest test to the transduction pathway of putative signals that modulates the transcription htrA that led to identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>This basic pair G:C is also the strongest determinant in the sequence selection experiment that led to the identification of BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>This basic pair G:C is also the strongest determinant in this leading to a substantial diversity of isoforms of nebulin and nebulette (Lagrange et al., 1998).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>This basic pair G:C is also the strongest determinant in this that led to a substantial diversity of isoforms of nebulin and nebulae (Lagrange et al., 1998).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>This basic pair G:C is also the strongest determinant in this that led to a substantial diversity of isoforms of nebulin and nebulette (Lagrange et al., 1998).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>This can lead to a wide diversity of nebulae and nebulae, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>This can lead to a wide diversity of nebulin and nebule isoforms, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>This can lead to synergistic activation of ANA and other target promoters of MEF2, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>This data suggests that Crl stimulates sigma (S) activity led to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>This data suggests that Crl stimulates sigma activity (S) can lead to an increase in the transcription rate of a subset of rpoS genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>This data suggests that Crl stimulates sigma activity (S) can lead to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>This data suggests that Crl stimulates sigma activity (S) has led to an increase in the transcription rate of a subset of rpoS genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>This data suggests that Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of rpoS genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>This data suggests that Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>This data suggests that Crl stimulates sigma activity (S) will lead to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>This data suggests that Crl stimulates sigma activity (S) will lead to an increase in the transcription rate of a subset of rpoS genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>This data suggests that Crl stimulates sigma activity (S) will lead to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>This data suggests that DNA (nCaRE)-ref1 led to C2+e transcriptional deletion that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>This data suggests that DNA (nCaRE)-ref1 was able to lead to C2+e transcriptional deletion that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>This data suggests that G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 has led to a substitution of a positive load in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>This data suggests that G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 was able to lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>This data suggests that GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D led to a synergistic activation of 40 to 50 times that of the ANA promoter that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>This data suggests that GATA-4 cotransformation with MEF2A, MEF2C or MEF2D can lead to a 40 to 50-fold synergistic activation of the aF promoter that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>This data suggests that GM2 was able to lead to a neurological disease that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>This data suggests that Loss of TreR function can lead to derepression of treB that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>This data suggests that Loss of TreR function will lead to derepression of treB that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>This data suggests that This can lead to a wide diversity of nebulin and nebule isoforms that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>This data suggests that This has led to synergistic activation of ANA and other target promoters of MEF2 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>This data suggests that This led to a wide diversity of nebulae and nebulae that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>This data suggests that This led to a wide diversity of nebulins and nebule isoforms working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>This data suggests that This led to synergistic activation of ANA and other target promoters of MEF2 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>This data suggests that a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>This data suggests that a C--A transversion after the last intron sternalization aceptors of the ERCC-3 can lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>This data suggests that a C--A transversion after the last intron sternalization aceptors of the ERCC-3 led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>This data suggests that a closer analysis of the putative signal transduction pathway that modulates HtrA transcription has led to the identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>This data suggests that a closer analysis of the putative signal transduction pathway that modulates HtrA transcription will lead to the identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>This data suggests that a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription was able to lead to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>This data suggests that a closer examination of the transduction pathway of putative signals that modulates the transcription htrA was able to lead to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>This data suggests that a mutation point (GTC---ATC) in codon 383 can lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>This data suggests that a point mutation (GTC---ATC) in codon 383 led to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>This data suggests that a point mutation at the application site of the third intron can lead to ligation of the second to the fourth exon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>This data suggests that a point mutation at the pulse site of the third intron led to ligation of the second to the fourth intron that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>This data suggests that a point mutation at the pulse site of the third intron will lead to ligation of the second to the fourth exon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>This data suggests that a punctual mutation (GTC----ATC) in codon 383 has led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>This data suggests that a punctual mutation (GTC----ATC) in codon 383 has led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>This data suggests that a punctual mutation (GTC----ATC) in codon 383 led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>This data suggests that a punctual mutation (GTC----ATC) in codon 383 led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>This data suggests that a punctual mutation (GTC----ATC) in codon 383 was able to lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>This data suggests that closer to the transduction pathway of the putative signal that modulates htrA transcription has led to the identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>This data suggests that closer to the transduction pathway of the putative signal that modulates htrA transcription was able to lead to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>This data suggests that closer to the transduction pathway of the putative signal that modulates the htrA transcription led to the identification of two new genes working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>This data suggests that cut switch at 5 ends of the intron 5 has led to normal exon 5 and portion of exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>This data suggests that cut switch at 5 ends of the intron 5 led to normal exon 5 and portion of exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>This data suggests that genetic deficiency of the GM2 activator can lead to a neurological disease that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>This data suggests that genetic deficiency of the GM2 activator was able to lead to a neurological disorder that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>This data suggests that mutation of cut at 5 ends of the intron 5 has led to abnormal exon 5 and portion of exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>This data suggests that mutation of cut at 5 ends of the intron 5 led to abnormal exon 5 and portion of exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>This data suggests that mutation of cutting at 5 ends of the intron 5 has led to normal exon 5 and portion of exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>This data suggests that mutation of cutting at 5 ends of the intron 5 will lead to normal exon 5 and portion of exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>This data suggests that phosphorylation of MuSK NPXY site has led to recruitment of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>This data suggests that phosphorylation of the MuSK site NPXY can lead to recovery of a protein bound to phosphorosine that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>This data suggests that phosphorylation of the NPXY MuSK site was able to lead to recruitment of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>This data suggests that phosphorylation of the site NPXY MuSK can lead to recovery of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>This data suggests that phosphorylation of the site NPXY MuSK has led to recovery of a domain protein bound to phosphorosine that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>This data suggests that sequence selection experience can lead to BRE identification that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>This data suggests that this led to a substantial diversity of isoforms of nebulin and nebulette that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>This data suggests that this was able to lead to a substantial diversity of isoforms of nebulin and nebulette that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>This data suggests that this will lead to a substantial diversity of isoforms of nebulin and nebulette that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>This data suggests that two changes in the picture and one mutation at the fitting site was able to lead to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>This data suggests that with two exchanges of frames and a mutation at the fitting site can lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>This data suggests that with two exchanges of frames and a mutation at the fitting site led to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>This data suggests that with two exchanges of frames and a mutation at the fitting site led to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>This data suggests that with two exchanges of frames and a mutation at the fitting site will lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>This has led in a wide diversity of nebulins and nebule isoforms, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>This has led in synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>This is able to lead to synergistic activation of ANA and other target promoters of MEF2 (figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>This leading to a wide diversity of nebulae and nebulae, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>This leading to a wide diversity of nebulins and nebule isoforms, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>This leads to a wide diversity of nebulae and nebulae coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>This led a wide diversity of nebulin and nebule isoforms to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>This led to a wide diversity of nebulae and nebulae, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>This led to a wide diversity of nebulae and nebulae, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>This led to a wide diversity of nebulin and nebule isoforms (figuration 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>This led to a wide diversity of nebulin and nebule isoforms, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>This led to a wide diversity of nebulins and nebule isoforms, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>This may lead to a wide diversity of nebulins and nebule isoforms (figure 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>This patient DNA contains Crl stimulates sigma activity (S) that can lead to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>This patient DNA contains Crl stimulates sigma activity (S) which leads to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>This patient DNA contains DNA (nCaRE)-ref1 leads to C2+ and transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>This patient DNA contains DNA (nCaRE)-ref1 that can lead to C2+e transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>This patient DNA contains G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>This patient DNA contains GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D that can lead to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>This patient DNA contains GATA-4 cotransformation with MEF2A, MEF2C or MEF2D leads to a 40 to 50-fold synergistic activation of the aF promoter.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>This patient DNA contains GM2 genetic deficiency which leads to a neurological disorder.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>This patient DNA contains This leads to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>This patient DNA contains This that can lead to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>This patient DNA contains This which leads to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>This patient DNA contains a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele that can lead to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>This patient DNA contains a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>This patient DNA contains a C--A transversion after the last intron sternalization aceptors of the ERCC-3 leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>This patient DNA contains a closer analysis of the putative signal transduction pathway that modulates HtrA transcription which leads to the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>This patient DNA contains a closer examination of the transduction pathway of putative signals that modulates the transcription htrA leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>This patient DNA contains a closer examination of the transfer pathway of putative signals that modulates the transcription htrA which leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>This patient DNA contains a mutation point (GTC---ATC) in codon 383 that can lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>This patient DNA contains a point mutation at the application site of the third intron that can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>This patient DNA contains a point mutation at the application site of the third intron which leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>This patient DNA contains a point mutation at the pulse site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>This patient DNA contains closer to the transduction pathway of the putative signal that modulates htrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>This patient DNA contains genetic deficiency of the GM2 activator leads to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>This patient DNA contains mutation of cutting at 5 ends of the intron 5 leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>This patient DNA contains nCaRE leads to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>This patient DNA contains phosphorylation of the MuSK site NPXY leads to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>This patient DNA contains phosphorylation of the MuSK site NPXY that can lead to capture of a phosphorosine binding protein.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>This patient DNA contains phosphorylation of the MuSK site NPXY that can lead to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>This patient DNA contains phosphorylation of the NPXY MuSK site which leads to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>This patient DNA contains phosphorylation of the NPXY site of MuSK which leads to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>This patient DNA contains the closest test to the putative signal transduction pathway that modulates the htrA transcription which leads to identification of two new genes.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>This patient DNA contains the sequence selection experiment which leads to the identification of BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>This patient DNA contains this which leads to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>This patient DNA contains with two exchanges of frames and a mutation at the fitting site leads to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>This patient DNA contains with two exchanges of frames and a mutation at the fitting site that can lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>This patients DNA contains the loss of OmpF leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">the loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>This was caused by Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D that may lead to a 40 to 50-fold synergistic activation of the ANA promoter.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>This was caused by Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D which led to a 40 to 50-fold synergistic activation of the ANA promoter.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>This was caused by Crl stimulates sigma (S) activity which led to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>This was caused by Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>This was caused by Crl stimulates sigma activity (S) that can lead to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>This was caused by Crl stimulates sigma activity (S) that led to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>This was caused by Crl stimulates sigma activity (S) that may lead to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>This was caused by Crl stimulates sigma activity (S) which has led to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>This was caused by DNA (nCaRE)-ref1 leading to C2+e transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>This was caused by DNA (nCaRE)-ref1 which has led to C2+e transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>This was caused by G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 that leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>This was caused by G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 which has led to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>This was caused by G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 which led to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>This was caused by G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>This was caused by G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>This was caused by GATA-4 co-transfection with MEF2A, MEF2C or MEF2D leads to a synergistic activation of 40 to 50 folds of the promoter ANA.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>This was caused by GATA-4 co-transfection with MEF2A, MEF2C or MEF2D that led to a synergistic activation of 40 to 50 folds of the promoter ANA.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>This was caused by GATA-4 co-transfection with MEF2A, MEF2C or MEF2D which has led to a synergistic activation of 40 to 50 folds of the promoter ANA.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>This was caused by GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D leading to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>This was caused by GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D that may lead to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>This was caused by GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D which led to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>This was caused by GATA-4 cotransformation with MEF2A, MEF2C or MEF2D which leading to a 40 to 50-fold synergistic activation of the aF promoter.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>This was caused by GM2 genetic deficiency that leads to a neurological disorder.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>This was caused by GM2 genetic deficiency which has led to a neurological disorder.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>This was caused by GM2 genetic deficiency which led to a neurological disorder.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>This was caused by GM2 leading to a neurological disease.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>This was caused by GM2 that may lead to a neurological disease.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>This was caused by Loss of TreR function leads to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>This was caused by Loss of TreR function that leads to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>This was caused by This leads to a wide diversity of nebulin and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>This was caused by This that can lead to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>This was caused by This that can lead to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>This was caused by This that leads to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>This was caused by This that led to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>This was caused by This that led to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>This was caused by This that may lead to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>This was caused by This which has led to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>This was caused by This which leading to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>This was caused by This which led to a wide diversity of nebulin and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>This was caused by a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele that can lead to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>This was caused by a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele which led to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>This was caused by a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>This was caused by a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele that can lead to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>This was caused by a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele which led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>This was caused by a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>This was caused by a C--A transversion after the last intron sternalization aceptors of the ERCC-3 which led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>This was caused by a closer analysis of the putative signal transduction pathway that modulates HtrA transcription that leads to the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>This was caused by a closer analysis of the putative signal transduction pathway that modulates HtrA transcription that may lead to the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>This was caused by a closer examination of the transduction pathway of putative signals that modulates the transcription htrA that can lead to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>This was caused by a closer examination of the transfer pathway of putative signals that modulates the transcription htrA that leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>This was caused by a mutation point (GTC---ATC) in codon 383 leads to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>This was caused by a mutation point (GTC---ATC) in codon 383 that led to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>This was caused by a point mutation (GTC---ATC) in codon 383 that leads to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>This was caused by a point mutation (GTC---ATC) in codon 383 which has led to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>This was caused by a point mutation at the application site of the third intron that leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>This was caused by a point mutation at the application site of the third intron that led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>This was caused by a point mutation at the pulse site of the third intron that led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>This was caused by a point mutation at the pulse site of the third intron which led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>This was caused by a punctual mutation (GTC----ATC) in codon 383 that may lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>This was caused by a punctual mutation (GTC----ATC) in codon 383 which led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>This was caused by closer to the transduction pathway of the putative signal that modulates htrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>This was caused by closer to the transduction pathway of the putative signal that modulates htrA transcription which leading to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>This was caused by closer to the transduction pathway of the putative signal that modulates the htrA transcription which led to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>This was caused by cut switch at 5 ends of the intron 5 leading to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>This was caused by cut switch at 5 ends of the intron 5 that can lead to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>This was caused by cut switch at 5 ends of the intron 5 which leading to abnormal exon 5 and exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>This was caused by genetic deficiency of the GM2 activator leads to a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>This was caused by growth of scherichia coli in the presence of nitrate or nitrite leading to a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>This was caused by mutation of cutting at 5 ends of the intron 5 leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>This was caused by mutation of cutting at 5 ends of the intron 5 that can lead to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>This was caused by mutation of cutting at 5 ends of the intron 5 that may lead to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>This was caused by phosphorylation of MuSK NPXY site leads to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>This was caused by phosphorylation of MuSK NPXY site that can lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>This was caused by phosphorylation of the MuSK site NPXY leading to capture of a phosphorosine binding protein.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>This was caused by phosphorylation of the MuSK site NPXY leads to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>This was caused by phosphorylation of the MuSK site NPXY that can lead to capture of a phosphorosine binding protein.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>This was caused by phosphorylation of the NPXY MuSK site leads to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>This was caused by phosphorylation of the NPXY MuSK site that may lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>This was caused by phosphorylation of the NPXY MuSK site which led to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>This was caused by phosphorylation of the NPXY site of MuSK that may lead to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>This was caused by phosphorylation of the site NPXY MuSK leading to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>This was caused by phosphorylation of the site NPXY MuSK that leads to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>This was caused by phosphorylation of the site NPXY MuSK that may lead to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>This was caused by phosphorylation of the site NPXY MuSK which leading to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>This was caused by phosphorylation of the site NPXY MuSK which led to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>This was caused by sequence selection experience which has led to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>This was caused by sequence selection experience which led to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>This was caused by the closest test to the putative signal transduction pathway that modulates the htrA transcription that leads to identification of two new genes.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>This was caused by the closest test to the transduction pathway of putative signals that modulates the transcription htrA leading to identification of two new genes.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>This was caused by the closest test to the transduction pathway of putative signals that modulates the transcription htrA leads to identification of two new genes.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>This was caused by the sequence selection experiment that can lead to the identification of BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>This was caused by this that can lead to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>This was caused by this that leads to a substantial diversity of isoforms of nebulin and nebulette.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>This was caused by this that led to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>This was caused by this which leading to a substantial diversity of isoforms of nebulin and nebulette.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>This was caused by two changes in the picture and one mutation at the fitting site leading to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>This was caused by with two exchanges of frames and a mutation at the fitting site that can lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>This was caused by with two exchanges of frames and a mutation at the fitting site that leads to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>This was caused by with two exchanges of frames and a mutation at the fitting site that led to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>This was caused by with two exchanges of frames and a mutation at the fitting site that may lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>This will lead to a wide diversity of nebulin and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>This, in turn, is leading to a wide diversity of nebulae and nebulae regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to a C---A transversion following the helix of the last intron of the ERCC-3 allele.</text>
                    <arg n="0">a C---A transversion following the helix of the last intron of the ERCC-3 allele</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, will lead to two changes in the picture and one mutation at the ear site.</text>
                    <arg n="0">two changes in the picture and one mutation at the ear site</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to nCaRE.</text>
                    <arg n="0">nCaRE</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to two changes in the picture and one mutation at the ear site.</text>
                    <arg n="0">two changes in the picture and one mutation at the ear site</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>a 45% drop in expression is led by growth of scherichia coli in the presence of nitrate or nitrite.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>a 45% drop in expression is led to growth of scherichia coli in the presence of nitrate or nitrite.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele can lead to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein (figuration 3A).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele can lead to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele can lead to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele led to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein (figuration 3A).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele will lead to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele can lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele is able to lead an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C (picture 3A).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele is able to lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C (figure 3A).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele is able to lead to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele led an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C (figuration 3A).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele led to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele may lead to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele will lead to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele is able to lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C (figure 3A).</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C (figuration 3A).</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele may lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C (figure 3A).</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele was able to lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C when the cells were grown in rich environments.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>a C--A transversion after the last intron sternalization aceptors of the ERCC-3 can lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid (figuration 3A).</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>a C--A transversion after the last intron sternalization aceptors of the ERCC-3 is leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>a C--A transversion after the last intron sternalization aceptors of the ERCC-3 leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>a C--A transversion after the last intron sternalization aceptors of the ERCC-3 will lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>a closer analysis of the putative signal transduction pathway that modulates HtrA transcription has led in the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>a closer analysis of the putative signal transduction pathway that modulates HtrA transcription leads to the identification of two new genes coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>a closer analysis of the putative signal transduction pathway that modulates HtrA transcription led the identification of two new genes to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription led the identification of two new genes to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription led to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription, in turn, is leading to the identification of two new genes regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the transcription htrA has led in the identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the transcription htrA is able to lead to the identification of two new genes (figure 3A).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the transcription htrA led to the identification of two new genes (figuration 3A).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the transcription htrA may lead to the identification of two new genes coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>a closer examination of the transfer pathway of putative signals that modulates the transcription htrA can lead to the identification of two new genes (figuration 3A).</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>a closer examination of the transfer pathway of putative signals that modulates the transcription htrA can lead to the identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>a closer examination of the transfer pathway of putative signals that modulates the transcription htrA is able to lead to the identification of two new genes (figure 3A).</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>a closer examination of the transfer pathway of putative signals that modulates the transcription htrA will lead to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>a mutation point (GTC---ATC) in codon 383 can lead to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>a mutation point (GTC---ATC) in codon 383 is able to lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop (figure 3A).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>a mutation point (GTC---ATC) in codon 383 is able to lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>a mutation point (GTC---ATC) in codon 383 leads to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>a mutation point (GTC---ATC) in codon 383 led the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>a mutation point (GTC---ATC) in codon 383 may lead to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>a mutation point (GTC---ATC) in codon 383 may lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>a mutation point (GTC---ATC) in codon 383 will lead to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>a mutation point (GTC---ATC) in codon 383, in turn, is leading to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>a neurological disorder is led by genetic deficiency of the GM2 activator.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>a neurological disorder was led to GM2 genetic deficiency.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>a point mutation (GTC---ATC) in codon 383 leading to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>a point mutation (GTC---ATC) in codon 383 led to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>a point mutation (GTC---ATC) in codon 383 may lead to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop (figure 3A).</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>a point mutation (GTC---ATC) in codon 383 was able to lead to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop when the cells were grown in rich environments.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>a point mutation at the application site of the third intron has led in ligation of the second to the fourth exon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>a point mutation at the application site of the third intron is able to lead ligation of the second to the fourth exon (picture 3A).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>a point mutation at the application site of the third intron leading to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>a point mutation at the application site of the third intron led ligation of the second to the fourth exon to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>a point mutation at the application site of the third intron may lead to ligation of the second to the fourth exon (figure 3A).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>a point mutation at the pulse site of the third intron can lead to ligation of the second to the fourth exon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>a point mutation at the pulse site of the third intron can lead to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>a point mutation at the pulse site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>a point mutation at the pulse site of the third intron leads to ligation of the second to the fourth intron coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>a point mutation at the pulse site of the third intron led to ligation of the second to the fourth exon (figuration 3A).</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>a point mutation at the pulse site of the third intron may lead to ligation of the second to the fourth intron coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>a point mutation at the pulse site of the third intron may lead to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>a point mutation at the pulse site of the third intron will lead to ligation of the second to the fourth exon coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>a point mutation at the pulse site of the third intron will lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>a punctual mutation (GTC----ATC) in codon 383 can lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>a punctual mutation (GTC----ATC) in codon 383 has led in conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>a punctual mutation (GTC----ATC) in codon 383 is able to lead the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (picture 3A).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>a punctual mutation (GTC----ATC) in codon 383 led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter (figuration 3A).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>a punctual mutation (GTC----ATC) in codon 383 will lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>a punctual mutation (GTC----ATC) in codon 383 will lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>a punctual mutation (GTC----ATC) in codon 383, in turn, is leading to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>a substantial diversity of isoforms of nebulin and nebulae is led to this.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>a substantial diversity of isoforms of nebulin and nebulae was led to this.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>a substantial diversity of isoforms of nebulin and nebulette is led by this.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>a substantial diversity of isoforms of nebulin and nebulette was led by this.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>a substitution of a positive charge in a highly conserved transmembrane domain (R496S) is led to G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>a substitution of a positive load in a highly conserved transmembrane domain (R496S) was led by G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>a synergistic activation of 40 to 50 folds of the promoter ANA is led by GATA-4 co-transfection with MEF2A, MEF2C or MEF2D.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>a wide diversity of nebulin and nebule isoforms was led to This.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>a wide diversity of nebulins and nebule isoforms is led by This.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>abnormal exon 5 and exon 6 is led by cut switch at 5 ends of the intron 5.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase is led by Crl stimulates sigma activity (S).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>an increase in the transcription rate of a subset of rpoS genes in the stationary phase is led by Crl stimulates sigma activity (S).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>capture of a protein containing phosphorosine binding domains was led to phosphorylation of the MuSK site NPXY.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>closer to the transduction pathway of the putative signal that modulates htrA transcription leading to the identification of two new genes, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>closer to the transduction pathway of the putative signal that modulates htrA transcription leading to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription has led in the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription is able to lead to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription leading to the identification of two new genes, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription leading to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription leads to the identification of two new genes coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription led to the identification of two new genes, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription may lead to the identification of two new genes (figure 3A).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription will lead to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter is led to a punctual mutation (GTC----ATC) in codon 383.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter was led to a punctual mutation (GTC----ATC) in codon 383.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>cut switch at 5 ends of the intron 5 can lead to abnormal exon 5 and exon 6 (figuration 3A).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>cut switch at 5 ends of the intron 5 can lead to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>cut switch at 5 ends of the intron 5 is able to lead to abnormal exon 5 and exon 6 (figure 3A).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>cut switch at 5 ends of the intron 5 is able to lead to abnormal exon 5 and exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>cut switch at 5 ends of the intron 5 leading to abnormal exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>cut switch at 5 ends of the intron 5 leading to normal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>cut switch at 5 ends of the intron 5 leading to normal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>cut switch at 5 ends of the intron 5 leading to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>cut switch at 5 ends of the intron 5 led to abnormal exon 5 and exon 6 (figuration 3A).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>cut switch at 5 ends of the intron 5 may lead to abnormal exon 5 and exon 6 coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>derepression of treB is led to Loss of TreR function.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction is led to with two exchanges of frames and a mutation at the fitting site.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>genetic deficiency of the GM2 activator is able to lead a neurological disease (picture 3A).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>genetic deficiency of the GM2 activator is leading to a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>genetic deficiency of the GM2 activator leading to a neurological disease, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>genetic deficiency of the GM2 activator leading to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>genetic deficiency of the GM2 activator may lead to a neurological disease coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>genetic deficiency of the GM2 activator will lead to a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>growth of scherichia coli in the presence of nitrate or nitrite can lead to a 45% drop in expression (figuration 3A).</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>growth of scherichia coli in the presence of nitrate or nitrite can lead to a 45% drop in expression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>growth of scherichia coli in the presence of nitrate or nitrite can lead to a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>growth of scherichia coli in the presence of nitrate or nitrite leading to a 45% drop in expression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>growth of scherichia coli in the presence of nitrate or nitrite may lead to a 45% drop in expression coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>identification of two new genes is led by the closest test to the transduction pathway of putative signals that modulates the transcription htrA.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>ligation of the second to the fourth intron is led by a point mutation at the pulse site of the third intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>ligation of the second to the fourth intron is led to a point mutation at the pulse site of the third intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>mutation of cut at 5 ends of the intron 5 can lead to abnormal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>mutation of cut at 5 ends of the intron 5 has led in abnormal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>mutation of cut at 5 ends of the intron 5 has led in abnormal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>mutation of cut at 5 ends of the intron 5 is able to lead abnormal exon 5 and portion of exon 6 (picture 3A).</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>mutation of cut at 5 ends of the intron 5 leads to abnormal exon 5 and portion of exon 6 coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>mutation of cut at 5 ends of the intron 5 leads to abnormal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>mutation of cut at 5 ends of the intron 5 will lead to abnormal exon 5 and portion of exon 6 coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>mutation of cutting at 5 ends of the intron 5 can lead to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>mutation of cutting at 5 ends of the intron 5 has led in normal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>mutation of cutting at 5 ends of the intron 5 has led in normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>mutation of cutting at 5 ends of the intron 5 will lead to normal exon 5 and portion of exon 6 coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>nCaRE can lead to C2+e-mediated transcriptional supression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>nCaRE is able to lead to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>nCaRE is leading to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>nCaRE leading to C2+e-mediated transcriptional supression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>nCaRE leads to C2+e-mediated transcriptional supression coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>nCaRE led to C2+e-mediated transcriptional supression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>normal exon 5 and portion of exon 6 is led to mutation of cutting at 5 ends of the intron 5.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction was led by two changes in the picture and one mutation at the fitting site.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction was led to two changes in the picture and one mutation at the fitting site.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction is led to with two exchanges of frames and a mutation at the fitting site.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction was led by with two exchanges of frames and a mutation at the fitting site.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>phosphorylation of MuSK NPXY site can lead to recruitment of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>phosphorylation of MuSK NPXY site is able to lead recruitment of a domain protein bound to phosphotyrosine (picture 3A).</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>phosphorylation of MuSK NPXY site led to recruitment of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>phosphorylation of MuSK NPXY site may lead to recruitment of a domain protein bound to phosphotyrosine (figure 3A).</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>phosphorylation of the MuSK site NPXY can lead to recovery of a protein bound to phosphorosine, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>phosphorylation of the MuSK site NPXY has led in recovery of a protein bound to phosphorosine, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>phosphorylation of the MuSK site NPXY is able to lead to recovery of a protein bound to phosphorosine (figure 3A).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>phosphorylation of the MuSK site NPXY leading to recovery of a protein bound to phosphorosine, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>phosphorylation of the MuSK site NPXY leads to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>phosphorylation of the MuSK site NPXY led capture of a protein containing phosphorosine binding domains to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>phosphorylation of the MuSK site NPXY led to capture of a protein containing phosphorosine binding domains, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>phosphorylation of the MuSK site NPXY led to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>phosphorylation of the MuSK site NPXY may lead to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>phosphorylation of the NPXY MuSK site has led in recruitment of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>phosphorylation of the NPXY MuSK site is able to lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>phosphorylation of the NPXY MuSK site led to recruitment of a domain protein bound to phosphotyrosine (figure 3A).</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>phosphorylation of the NPXY site of MuSK can lead to recovery of a domain protein bound to phosphotyrosine (figuration 3A).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>phosphorylation of the NPXY site of MuSK is able to lead recovery of a domain protein bound to phosphotyrosine (picture 3A).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>phosphorylation of the NPXY site of MuSK is able to lead to recovery of a domain protein bound to phosphotyrosine (figure 3A).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>phosphorylation of the NPXY site of MuSK leading to recovery of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>phosphorylation of the site NPXY MuSK has led in recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>phosphorylation of the site NPXY MuSK is able to lead to recovery of a domain protein bound to phosphorosine (figure 3A).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>phosphorylation of the site NPXY MuSK is able to lead to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>phosphorylation of the site NPXY MuSK leading to recovery of a domain protein bound to phosphorosine, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>phosphorylation of the site NPXY MuSK leading to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>phosphorylation of the site NPXY MuSK leads to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>phosphorylation of the site NPXY MuSK led recovery of a domain protein bound to phosphorosine to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>recovery of a domain protein bound to phosphotyrosine is led to phosphorylation of the site NPXY MuSK.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>sequence selection experience led BRE identification to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>sequence selection experience led to BRE identification (figuration 3A).</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>sequence selection experience, in turn, is leading to BRE identification regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>the closest test to the putative signal transduction pathway that modulates the htrA transcription leading to identification of two new genes.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>the closest test to the putative signal transduction pathway that modulates the htrA transcription led identification of two new genes to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>the closest test to the putative signal transduction pathway that modulates the htrA transcription led to identification of two new genes (figure 3A).</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>the closest test to the putative signal transduction pathway that modulates the htrA transcription may lead to identification of two new genes.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>the closest test to the putative signal transduction pathway that modulates the htrA transcription was able to lead to identification of two new genes when the cells were grown in rich environments.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>the closest test to the transduction pathway of putative signals that modulates the transcription htrA is able to lead to identification of two new genes.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>the closest test to the transduction pathway of putative signals that modulates the transcription htrA will lead to identification of two new genes.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop was led to a mutation point (GTC---ATC) in codon 383.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter is led to a punctual mutation (GTC----ATC) in codon 383.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter was led to a punctual mutation (GTC----ATC) in codon 383.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>the identification of two new genes is led to a closer examination of the transfer pathway of putative signals that modulates the transcription htrA.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>the identification of two new genes was led to a closer analysis of the putative signal transduction pathway that modulates HtrA transcription.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>the sequence selection experiment can lead to the identification of BRE (figuration 3A).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>the sequence selection experiment is able to lead the identification of BRE (picture 3A).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>the sequence selection experiment is leading to the identification of BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>the sequence selection experiment led the identification of BRE to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>the sequence selection experiment led to the identification of BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>the sequence selection experiment may lead to the identification of BRE (figure 3A).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>this can lead to a substantial diversity of isoforms of nebulin and nebulette, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>this is able to lead to a substantial diversity of isoforms of nebulin and nebulae (figure 3A).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>this may lead to a substantial diversity of isoforms of nebulin and nebulette coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>this was able to lead to a substantial diversity of isoforms of nebulin and nebulae when the cells were grown in rich environments.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>this will lead to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>this, in turn, is leading to a substantial diversity of isoforms of nebulin and nebulette regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>two changes in the picture and one mutation at the fitting site is able to lead to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction (figure 3A).</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>with two exchanges of frames and a mutation at the fitting site can lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction (figuration 3A).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>with two exchanges of frames and a mutation at the fitting site can lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>with two exchanges of frames and a mutation at the fitting site is able to lead oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction (picture 3A).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>with two exchanges of frames and a mutation at the fitting site is able to lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>with two exchanges of frames and a mutation at the fitting site leads to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>with two exchanges of frames and a mutation at the fitting site led to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>with two exchanges of frames and a mutation at the fitting site led to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>with two exchanges of frames and a mutation at the fitting site may lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>with two exchanges of frames and a mutation at the fitting site may lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>7 absent mutations, 2 mutations DNA of patients contains This allele that can lead to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>7 absent mutations, 2 mutations basic pair G:C is also the strongest determinant in This that leads to shifting in frames (Lagrange et al., 1998).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>7 absent mutations, 2 mutations leading to shifting in frames, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>7 absent mutations, 2 mutations led to shifting in frames, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>7 absent mutations, 2 mutations patient DNA contains This leads to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>7 absent mutations, 2 mutations was caused by This leads to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>7 absent mutations, 2 mutations was caused by This which has led to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>7 mutations without sense, 2 mutations base pair G:C is also the strongest determinant in This that led to table transfer (Lagrange et al., 1998).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>7 mutations without sense, 2 mutations basic pair G:C is also the strongest determinant in This that leads to table transfer (Lagrange et al., 1998).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>7 mutations without sense, 2 mutations can lead to table transfer, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>7 mutations without sense, 2 mutations data suggests that This led to table transfer working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>7 mutations without sense, 2 mutations has led in table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>7 mutations without sense, 2 mutations is able to lead to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>7 mutations without sense, 2 mutations leading to table transfer, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>7 mutations without sense, 2 mutations patient DNA contains This leads to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>7 mutations without sense, 2 mutations was caused by This that can lead to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>7 mutations without sense, 2 mutations, in turn, is leading to table transfer regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>7 senseless mutations, 2 mutations DNA of patients contains This that led to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>7 senseless mutations, 2 mutations base pair G:C is also the strongest determinant in This leads to frame shift (Lagrange et al., 1998).</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>7 senseless mutations, 2 mutations base pair G:C is also the strongest determinant in This that has led to frame shift (Lagrange et al., 1998).</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>7 senseless mutations, 2 mutations data suggests that This led to frame shift that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>7 senseless mutations, 2 mutations has led in frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>7 senseless mutations, 2 mutations led to frame shift, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>7 senseless mutations, 2 mutations may lead to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>7 senseless mutations, 2 mutations was caused by This that can lead to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>7 senseless mutations, 2 mutations was caused by This that leads to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>7 senseless mutations, 2 mutations was caused by This which led to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>7 senseless mutations, 2 mutations will lead to frame shift coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>7 senseless mutations, 2 mutations will lead to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>Display of the SNU246 gene in yeast base pair G:C is also the strongest determinant in This that has led to a defect of in vivo splicing, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Display of the SNU246 gene in yeast basic pair G:C is also the strongest determinant in This that leads to a defect of in vivo splicing, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Display of the SNU246 gene in yeast can lead to a defect of in vivo splicing, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Display of the SNU246 gene in yeast is leading to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Display of the SNU246 gene in yeast led to a defect of in vivo splicing, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Display of the SNU246 gene in yeast was caused by This that leads to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Display of the SNU246 gene in yeast was caused by This that led to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Display of the SNU246 gene in yeast was caused by This that may lead to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Display of the SNU246 gene in yeast was caused by This which has led to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Display of the SNU246 gene in yeast was caused by This which led to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 basic pair G:C is also the strongest determinant in This that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 data suggests that This has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 data suggests that This will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (figure 3A).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 patient DNA contains This which leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) when the cells were grown in rich environments.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 was caused by This which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14, in turn, is leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 DNA of patients contains This allele that can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 data suggests that This led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 data suggests that This was able to lead to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 data suggests that This will lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 has led in a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S) (figuration 3A).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (figuration 3A).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (figure 3A).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (figure 3A).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 patient DNA contains This that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This that leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This that may lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This that has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 data suggests that This has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 data suggests that This was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 patient DNA contains This leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This that has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 basic pair G:C is also the strongest determinant in This leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) when the cells were grown in rich environments.</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This that can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 DNA of patients contains This allele that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This that has led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 basic pair G:C is also the strongest determinant in This that led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 data suggests that This has led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This that leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This which leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 DNA of patients contains This allele that can lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 basic pair G:C is also the strongest determinant in This leading to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 data suggests that This has led to a substitution of a positive load in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (figuration 3A).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive load in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive load in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 may lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (figure 3A).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 patient DNA contains This leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 was able to lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S) when the cells were grown in rich environments.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 was caused by This leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 was caused by This that can lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>In 7 senseless mutations, 2 mutations homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>In G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>In G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>In G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>In a complex coupling site mutation homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>In a complex coupling site mutation homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>In a complex mutation of the coupling site homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>In a point mutation at the application site of the third intron homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction 7 senseless mutations, 2 mutations leads to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction 7 senseless mutations, 2 mutations-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a complex mutation of the coupling site leads to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a complex mutation of the coupling site leads to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction growth of Escherichia coli in the presence of nitrate or nitrite-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction inactivation of the MEF2C gene-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction the 5-end mutation of the intron 5 leads to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction the mutation of the splice at 5 ends of the intron 5 leads to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction 7 mutations without sense, 2 mutations-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction a complex coupling site mutation-ref1) was able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction disorganization of the SNU246 gene in the yeast-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction loss of the TreR function-ref1 had led to transcriptional suppression C2+e.</text>
                    <arg n="0">loss of the TreR function</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction the different amino acid terminals-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">the different amino acid terminals</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction this mutation at 5 ends of the intron 5-ref1) was able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction Display of the SNU246 gene in yeast leads to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a point mutation at the splicing 5 site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction disorganization of the SNU246 gene in the yeast leads to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction the different amino terminals leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction two frame shifts and a mutation of the splice site leads to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction 7 absent mutations, 2 mutations-ref1 is able to lead to transcriptional suppression shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction growth of Escherichia coli in the presence of nitrate or nitrite-ref1 is able to lead to transcriptional suppression a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction growth of Escherichia coli in the presence of nitrate or nitrite-ref1 is able to lead to transcriptional suppression a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction the mutation of the splice at 5 ends of the intron 5-ref1 is able to lead to transcriptional suppression the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction two frameshifts and a splice site mutation-ref1 is able to lead to transcriptional suppression truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>In disorganization of the SNU246 gene in the yeast homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>In growth of Escherichia coli in the presence of nitrate or nitrite homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>In inactivation of the MEF2C gene homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>In inactivation of the MEF2C gene homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>In inactivation of the MEF2C gene homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>In inactivation of the MEF2C gene homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>In inactivation of the MEF2C gene homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>In loss of the TreR function homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>In the 5-end mutation of the intron 5 homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>In the distinct termini amino acid homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>In the mutation of the splice at 5 ends of the intron 5 homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>In the mutation of the splice at 5 ends of the intron 5 homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>In this homologous part of genes, GBP lacks an exon due to G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>In this homologous part of genes, GBP lacks an exon due to G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>In this homologous part of genes, GBP lacks an exon due to a complex coupling site mutation, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>In this homologous part of genes, GBP lacks an exon due to a complex mutation of the coupling site, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>In this homologous part of genes, GBP lacks an exon due to the different amino acid terminals, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>In this homologous part of genes, GBP lacks an exon due to the different amino terminals, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>In this homologous part of genes, GBP lacks an exon due to this mutation at 5 ends of the intron 5, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>In this homologous part of genes, GPB does not have an exon due to G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14, which inactivates the pulse event of the 5th and may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>In this homologous part of genes, GPB does not have an exon due to a complex mutation of the coupling site, which inactivates the pulse event of the 5th and may lead to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>In this homologous part of genes, GPB does not have an exon due to a complex mutation of the coupling site, which inactivates the pulse event of the 5th and may lead to an abnormal JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>In this homologous part of genes, GPB does not have an exon due to a point mutation at the application site of the third intron, which inactivates the pulse event of the 5th and may lead to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>In this homologous part of genes, GPB does not have an exon due to inactivation of the MEF2C gene, which inactivates the pulse event of the 5th and may lead to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>In this homologous part of genes, GPB does not have an exon due to loss of the TreR function, which inactivates the pulse event of the 5th and may lead to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>In this homologous part of genes, GPB does not have an exon due to the 5-end mutation of the intron 5, which inactivates the pulse event of the 5th and may lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>In this homologous part of genes, GPB does not have an exon due to the different amino acid terminals, which inactivates the pulse event of the 5th and may lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>In this homologous part of genes, GPB does not have an exon due to this mutation at 5 ends of the intron 5, which inactivates the pulse event of the 5th and may lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>In this homologous part of the genes, GBP does not have an exon due to G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14, which inactivates the pulse segmentation event and leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>In this homologous part of the genes, GBP does not have an exon due to G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14, which inactivates the pulse segmentation event and leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>In this homologous part of the genes, GBP does not have an exon due to a complex mutation of the coupling site, which inactivates the pulse segmentation event and leads to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>In this homologous part of the genes, GBP does not have an exon due to a complex mutation of the coupling site, which inactivates the pulse segmentation event and leads to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>In this mutation at 5 ends of the intron 5 homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>In two frameshifts and a splice site mutation homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>The 7 absent mutations, 2 mutations leads to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>The 7 mutations without sense, 2 mutations will lead to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>The 7 senseless mutations, 2 mutations will lead to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>The G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>The G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 can lead to the a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to the a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to the a substitution of a positive charge in a highly conserved transmembrane domain (R496S) appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 will lead to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>The G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to the a substitution of a positive charge in a highly conserved transmembrane domain (R496S) appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>The a complex mutation of the coupling site leads to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>The a complex mutation of the coupling site leads to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>The a complex mutation of the coupling site leads to the an altered JNA, resulting in a premature arrest codon appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>The a complex mutation of the coupling site led to the an abnormal JNA, resulting in a premature arrest codon appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>The a complex mutation of the coupling site led to the an abnormal JNA, resulting in a premature arrest codon appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>The a complex mutation of the coupling site will lead to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>The a point mutation at the splicing 5 site of the third intron will lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>The disorganization of the SNU246 gene in the yeast leads to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>The growth of Escherichia coli in the presence of nitrate or nitrite leads to the a 45% expression decrease appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>The identified mutations include: 7 mutations without sense, 2 mutations leading to A1 (proteins of OA1 vegetated; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>The identified mutations include: a point mutation at the application site of the third intron leading to A1 (proteins of OA1 vegetated; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>The identified mutations include: disorganization of the SNU246 gene in the yeast leading to A1 (proteins of OA1 vegetated; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>The identified mutations include: the distinct termini amino acid leading to A1 (proteins of OA1 vegetated; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>The identified mutations include: this mutation at 5 ends of the intron 5 leading to A1 (proteins of OA1 vegetated; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>The inactivation of the MEF2C gene can lead to the morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>The inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>The inactivation of the MEF2C gene leads to the morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>The inactivation of the MEF2C gene leads to the morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>The inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>The inactivation of the MEF2C gene led to the morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>The inactivation of the MEF2C gene led to the morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>The loss of the TreR function leads to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>The mutations identified include: 7 absent mutations, 2 mutations leading to shifting in frames, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>The mutations identified include: 7 mutations without sense, 2 mutations that led to table transfer, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>The mutations identified include: G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>The mutations identified include: G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S), two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>The mutations identified include: a complex coupling site mutation that led to an altered ARNJ1 resulting in a premature stop codon, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>The mutations identified include: a point mutation at the application site of the third intron leading to ligation of the second to the fourth intron, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>The mutations identified include: growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% decrease in expression, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>The mutations identified include: inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>The mutations identified include: inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>The mutations identified include: inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>The mutations identified include: inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>The mutations identified include: loss of the TreR function that led to derepression of the treB, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>The mutations identified include: this mutation at 5 ends of the intron 5 that led to abnormal portion in exon 5 and exon 6, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>The mutations identified include: two frameshifts and a splice site mutation that led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>The the different amino terminals leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>The the mutation of the splice at 5 ends of the intron 5 will lead to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>The this mutation at 5 ends of the intron 5 led to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, is able to lead to 7 absent mutations, 2 mutations.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, is able to lead to the different amino acid terminals.</text>
                    <arg n="0">the different amino acid terminals</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, may lead to 7 mutations without sense, 2 mutations.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, may lead to 7 senseless mutations, 2 mutations.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, may lead to Display of the SNU246 gene in yeast.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, may lead to G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, may lead to growth of Escherichia coli in the presence of nitrate or nitrite.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to a complex mutation of the coupling site.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to a point mutation at the splicing 5 site of the third intron.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to loss of the TreR function.</text>
                    <arg n="0">loss of the TreR function</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to Display of the SNU246 gene in yeast.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to this mutation at 5 ends of the intron 5.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to two frameshifts and a splice site mutation.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to 7 absent mutations, 2 mutations.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to two frameshifts and a splice site mutation.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>The two frame shifts and a mutation of the splice site will lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>These data suggest that 7 mutations without sense, 2 mutations may lead to table transfer that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>These data suggest that 7 senseless mutations, 2 mutations led to frame shift that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>These data suggest that 7 senseless mutations, 2 mutations was able to lead to frame shift that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>These data suggest that G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>These data suggest that G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>These data suggest that G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>These data suggest that G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 was able to lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>These data suggest that inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>These data suggest that inactivation of the MEF2C gene may lead to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>These data suggest that inactivation of the MEF2C gene may lead to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>These data suggest that inactivation of the MEF2C gene was able to lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>These data suggest that loss of the TreR function led to derepression of the treB that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>These data suggest that the 5-end mutation of the intron 5 was able to lead to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>These data suggest that the different amino terminals was able to lead to the orientation of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>These data suggest that the distinct termini amino acid was able to lead to the direction of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>These data suggest that the mutation of the splice at 5 ends of the intron 5 led to the splice in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>These data suggest that this mutation at 5 ends of the intron 5 was able to lead to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>These data suggest that two frame shifts and a mutation of the splice site may lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>These data suggest that two frame shifts and a mutation of the splice site was able to lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>These data suggest that two frameshifts and a splice site mutation may lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>This DNA of patients contains 7 absent mutations, 2 mutations allele that can lead to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>This DNA of patients contains G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>This DNA of patients contains a complex mutation of the coupling site that led to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>This DNA of patients contains a point mutation at the application site of the third intron that led to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>This DNA of patients contains growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>This DNA of patients contains inactivation of the MEF2C gene allele that can lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>This DNA of patients contains inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>This DNA of patients contains inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>This DNA of patients contains inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>This DNA of patients contains the different amino acid terminals allele that can lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>This DNA of patients contains the mutation of the splice at 5 ends of the intron 5 that led to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>This DNA of patients contains two frame shifts and a mutation of the splice site that led to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>This DNA of patients contains two frameshifts and a splice site mutation allele that can lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>This base pair G:C is also the strongest determinant in 7 absent mutations, 2 mutations leads to shifting in frames (Lagrange et al., 1998).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>This base pair G:C is also the strongest determinant in 7 absent mutations, 2 mutations that led to shifting in frames (Lagrange et al., 1998).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>This base pair G:C is also the strongest determinant in 7 mutations without sense, 2 mutations that has led to table transfer (Lagrange et al., 1998).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>This base pair G:C is also the strongest determinant in Display of the SNU246 gene in yeast that led to a defect of in vivo splicing, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>This base pair G:C is also the strongest determinant in G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>This base pair G:C is also the strongest determinant in G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>This base pair G:C is also the strongest determinant in G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>This base pair G:C is also the strongest determinant in a complex coupling site mutation that has led to an altered ARNJ1 resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>This base pair G:C is also the strongest determinant in a complex mutation of the coupling site that has led to an abnormal JNA, resulting in a premature arrest codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>This base pair G:C is also the strongest determinant in a point mutation at the application site of the third intron that has led to ligation of the second to the fourth intron (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>This base pair G:C is also the strongest determinant in a point mutation at the splicing 5 site of the third intron leads to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>This base pair G:C is also the strongest determinant in a point mutation at the splicing 5 site of the third intron that led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene that has led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>This base pair G:C is also the strongest determinant in the 5-end mutation of the intron 5 that has led to abnormal portion in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>This base pair G:C is also the strongest determinant in this mutation at 5 ends of the intron 5 leading to abnormal portion in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>This base pair G:C is also the strongest determinant in two frame shifts and a mutation of the splice site that led to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>This base pair G:C is also the strongest determinant in two frameshifts and a splice site mutation that has led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>This base pair G:C is also the strongest determinant in two frameshifts and a splice site mutation that led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>This basic pair G:C is also the strongest determinant in G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that leads to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>This basic pair G:C is also the strongest determinant in G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>This basic pair G:C is also the strongest determinant in G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>This basic pair G:C is also the strongest determinant in G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>This basic pair G:C is also the strongest determinant in disorganization of the SNU246 gene in the yeast that led to in vivo splicing defect, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>This basic pair G:C is also the strongest determinant in growth of Escherichia coli in the presence of nitrate or nitrite that leads to a 45% expression decrease (Lagrange et al., 1998).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>This basic pair G:C is also the strongest determinant in growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>This basic pair G:C is also the strongest determinant in growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% expression decrease (Lagrange et al., 1998).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>This basic pair G:C is also the strongest determinant in inactivation of the MEF2C gene that leads to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>This basic pair G:C is also the strongest determinant in inactivation of the MEF2C gene that leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>This basic pair G:C is also the strongest determinant in inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>This basic pair G:C is also the strongest determinant in inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>This basic pair G:C is also the strongest determinant in loss of the TreR function leading to derepression of the treB (Lagrange et al., 1998).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>This basic pair G:C is also the strongest determinant in loss of the TreR function that leads to derepression of the treB (Lagrange et al., 1998).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>This basic pair G:C is also the strongest determinant in the 5-end mutation of the intron 5 leading to abnormal portion in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>This basic pair G:C is also the strongest determinant in the different amino acid terminals that leads to the orientation of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>This basic pair G:C is also the strongest determinant in the distinct termini amino acid leading to the direction of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>This basic pair G:C is also the strongest determinant in the mutation of the splice at 5 ends of the intron 5 leading to the abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>This basic pair G:C is also the strongest determinant in two frame shifts and a mutation of the splice site leading to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>This data suggests that 7 absent mutations, 2 mutations has led to shifting in frames that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>This data suggests that 7 absent mutations, 2 mutations will lead to shifting in frames that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>This data suggests that 7 mutations without sense, 2 mutations led to table transfer working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>This data suggests that 7 mutations without sense, 2 mutations was able to lead to table transfer that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>This data suggests that Display of the SNU246 gene in yeast can lead to a defect of in vivo splicing, indicating that the protein is essential for splicing that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>This data suggests that G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>This data suggests that G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>This data suggests that G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>This data suggests that G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>This data suggests that G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 will lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>This data suggests that a complex mutation of the coupling site was able to lead to an abnormal JAG1 mRNA, resulting in a premature halting codon that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>This data suggests that a point mutation at the application site of the third intron led to ligation of the second to the fourth intron that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>This data suggests that growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% expression decrease that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>This data suggests that growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% decrease in expression that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>This data suggests that growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% expression decrease that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>This data suggests that inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>This data suggests that inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>This data suggests that inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>This data suggests that inactivation of the MEF2C gene will lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>This data suggests that loss of the TreR function led to derepression of the treB that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>This data suggests that loss of the TreR function was able to lead to derepression of treB that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>This data suggests that the different amino acid terminals has led to the orientation of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>This data suggests that the mutation of the splice at 5 ends of the intron 5 can lead to the abnormal splice in exon 5 and exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>This data suggests that the mutation of the splice at 5 ends of the intron 5 will lead to the abnormal splice in exon 5 and exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>This data suggests that this mutation at 5 ends of the intron 5 can lead to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>This data suggests that this mutation at 5 ends of the intron 5 will lead to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>This data suggests that two frame shifts and a mutation of the splice site has led to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>This data suggests that two frame shifts and a mutation of the splice site will lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>This patient DNA contains 7 mutations without sense, 2 mutations leads to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>This patient DNA contains 7 senseless mutations, 2 mutations which leads to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>This patient DNA contains G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>This patient DNA contains G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>This patient DNA contains G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 that can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>This patient DNA contains G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>This patient DNA contains a complex mutation of the coupling site that can lead to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>This patient DNA contains growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>This patient DNA contains inactivation of the MEF2C gene that can lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>This patient DNA contains inactivation of the MEF2C gene which leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>This patient DNA contains inactivation of the MEF2C gene which leads to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>This patient DNA contains the different amino terminals leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>This patient DNA contains this mutation at 5 ends of the intron 5 that can lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>This patients DNA contains G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>This patients DNA contains the 5-end mutation of the intron 5 leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>This was caused by 7 absent mutations, 2 mutations leads to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>This was caused by 7 absent mutations, 2 mutations which leading to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>This was caused by G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 that can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that can lead to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 which has led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 which led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 which led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>This was caused by G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 that may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>This was caused by G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>This was caused by G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>This was caused by G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>This was caused by a complex coupling site mutation that may lead to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>This was caused by a complex mutation of the coupling site that led to an abnormal JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>This was caused by a complex mutation of the coupling site that may lead to an abnormal JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>This was caused by a point mutation at the application site of the third intron that can lead to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>This was caused by a point mutation at the application site of the third intron which leading to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>This was caused by disorganization of the SNU246 gene in the yeast leads to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>This was caused by growth of Escherichia coli in the presence of nitrate or nitrite that can lead to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>This was caused by growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>This was caused by growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>This was caused by inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>This was caused by inactivation of the MEF2C gene that can lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>This was caused by inactivation of the MEF2C gene that leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>This was caused by inactivation of the MEF2C gene that leads to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>This was caused by inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>This was caused by inactivation of the MEF2C gene that may lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>This was caused by loss of the TreR function leads to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>This was caused by the 5-end mutation of the intron 5 which led to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>This was caused by the different amino terminals which has led to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>This was caused by the different amino terminals which leading to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>This was caused by the mutation of the splice at 5 ends of the intron 5 that can lead to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>This was caused by the mutation of the splice at 5 ends of the intron 5 that may lead to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>This was caused by the mutation of the splice at 5 ends of the intron 5 which leading to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>This was caused by this mutation at 5 ends of the intron 5 that led to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>This was caused by this mutation at 5 ends of the intron 5 that may lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>This was caused by this mutation at 5 ends of the intron 5 which has led to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>This was caused by this mutation at 5 ends of the intron 5 which leading to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>This was caused by two frame shifts and a mutation of the splice site that can lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to 7 senseless mutations, 2 mutations.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to two frame shifts and a mutation of the splice site.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, will lead to G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, will lead to G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, will lead to a complex mutation of the coupling site.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, will lead to two frameshifts and a splice site mutation.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>Transduction of the MarA region from a sea strain, but not of a wild type, has led to 7 senseless mutations, 2 mutations.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>Transduction of the MarA region from a sea strain, but not of a wild type, has led to Display of the SNU246 gene in yeast.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>Transduction of the MarA region from a sea strain, but not of a wild type, has led to G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>Transduction of the MarA region from a sea strain, but not of a wild type, has led to a point mutation at the splicing 5 site of the third intron.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to 7 senseless mutations, 2 mutations.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to a point mutation at the splicing 5 site of the third intron.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to growth of Escherichia coli in the presence of nitrate or nitrite.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to the different amino terminals.</text>
                    <arg n="0">the different amino terminals</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to two frame shifts and a mutation of the splice site.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>a complex coupling site mutation base pair G:C is also the strongest determinant in This that has led to an altered ARNJ1 resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>a complex coupling site mutation data suggests that This has led to an altered ARNJ1 resulting in a premature stop codon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>a complex coupling site mutation is able to lead to an altered ARNJ1 resulting in a premature stop codon (figure 3A).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>a complex coupling site mutation leading to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>a complex coupling site mutation leads to an altered ARNJ1 resulting in a premature stop codon coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>a complex coupling site mutation led to an altered ARNJ1 resulting in a premature stop codon, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>a complex coupling site mutation may lead to an altered ARNJ1 resulting in a premature stop codon (figure 3A).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>a complex coupling site mutation was able to lead to an altered ARNJ1 resulting in a premature stop codon when the cells were grown in rich environments.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>a complex coupling site mutation was caused by This leading to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>a complex coupling site mutation was caused by This which leading to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>a complex mutation of the coupling site DNA of patients contains This that led to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>a complex mutation of the coupling site base pair G:C is also the strongest determinant in This that led to an abnormal JNA, resulting in a premature arrest codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>a complex mutation of the coupling site basic pair G:C is also the strongest determinant in This leading to an abnormal JAG1 mRNA, resulting in a premature halting codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>a complex mutation of the coupling site can lead to an abnormal JNA, resulting in a premature arrest codon (figuration 3A).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>a complex mutation of the coupling site can lead to an altered JNA, resulting in a premature arrest codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>a complex mutation of the coupling site data suggests that This led to an abnormal JAG1 mRNA, resulting in a premature halting codon working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>a complex mutation of the coupling site is able to lead to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>a complex mutation of the coupling site leading to an abnormal JAG1 mRNA, resulting in a premature halting codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>a complex mutation of the coupling site leading to an abnormal JNA, resulting in a premature arrest codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>a complex mutation of the coupling site leading to an altered JNA, resulting in a premature arrest codon, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>a complex mutation of the coupling site leads to an abnormal JNA, resulting in a premature arrest codon coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>a complex mutation of the coupling site led to an abnormal JAG1 mRNA, resulting in a premature halting codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>a complex mutation of the coupling site may lead to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>a complex mutation of the coupling site was caused by This that led to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>a complex mutation of the coupling site was caused by This which has led to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>a complex mutation of the coupling site, in turn, is leading to an abnormal JNA, resulting in a premature arrest codon regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>a point mutation at the application site of the third intron base pair G:C is also the strongest determinant in This that has led to ligation of the second to the fourth intron (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>a point mutation at the application site of the third intron base pair G:C is also the strongest determinant in This that led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>a point mutation at the application site of the third intron basic pair G:C is also the strongest determinant in This that leads to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>a point mutation at the application site of the third intron can lead to ligation of the second to the fourth intron (figuration 3A).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>a point mutation at the application site of the third intron is leading to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>a point mutation at the application site of the third intron leading to ligation of the second to the fourth intron, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>a point mutation at the application site of the third intron may lead to ligation of the second to the fourth intron coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>a point mutation at the application site of the third intron patient DNA contains This which leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>a point mutation at the application site of the third intron was caused by This leads to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>a point mutation at the application site of the third intron was caused by This that can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>a point mutation at the application site of the third intron was caused by This that leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>a point mutation at the application site of the third intron was caused by This that led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>a point mutation at the application site of the third intron was caused by This that led to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>a point mutation at the application site of the third intron was caused by This which led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>a point mutation at the application site of the third intron was caused by This which led to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>a point mutation at the splicing 5 site of the third intron can lead to ligation of the second to the fourth exon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>a point mutation at the splicing 5 site of the third intron can lead to ligation of the second to the fourth exon, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>a point mutation at the splicing 5 site of the third intron has led in ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>a point mutation at the splicing 5 site of the third intron is able to lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>a point mutation at the splicing 5 site of the third intron leads to ligation of the second to the fourth exon coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>a point mutation at the splicing 5 site of the third intron patient DNA contains This that can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>a point mutation at the splicing 5 site of the third intron was caused by This which has led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S) is led to G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) is led by G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) was led to G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) was led to G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>a substitution of a positive charge in a highly conserved transmembrane domain (R496S) is led by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>a substitution of a positive load in a highly conserved transmembrane domain (R496S) was led by G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>abnormal portion in exon 5 and exon 6 was led to the 5-end mutation of the intron 5.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>an altered JNA, resulting in a premature arrest codon is led by a complex mutation of the coupling site.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>an altered JNA, resulting in a premature arrest codon was led by a complex mutation of the coupling site.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>an altered JNA, resulting in a premature arrest codon was led to a complex mutation of the coupling site.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>derepression of treB was led to loss of the TreR function.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>disorganization of the SNU246 gene in the yeast DNA of patients contains This that led to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>disorganization of the SNU246 gene in the yeast base pair G:C is also the strongest determinant in This that led to in vivo splicing defect, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>disorganization of the SNU246 gene in the yeast data suggests that This can lead to in vivo splicing defect, indicating that the protein is essential for splicing that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>disorganization of the SNU246 gene in the yeast is able to lead in vivo splicing defect, indicating that the protein is essential for splicing (picture 3A).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>disorganization of the SNU246 gene in the yeast is leading to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>disorganization of the SNU246 gene in the yeast leading to in vivo splicing defect, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>disorganization of the SNU246 gene in the yeast led to in vivo splicing defect, indicating that the protein is essential for splicing (figuration 3A).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>disorganization of the SNU246 gene in the yeast may lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite DNA of patients contains This that led to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% expression decrease, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite data suggests that This led to a 45% decrease in expression that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite leading to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite leading to a 45% expression decrease, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite led to a 45% decrease in expression (figure 3A).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite led to a 45% decrease in expression, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite patient DNA contains This leads to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% decrease in expression when the cells were grown in rich environments.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite was caused by This that may lead to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite will lead to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>in vivo splicing defect, indicating that the protein is essential for splicing is led to disorganization of the SNU246 gene in the yeast.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>inactivation of the MEF2C gene DNA of patients contains This allele that can lead to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>inactivation of the MEF2C gene DNA of patients contains This that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>inactivation of the MEF2C gene DNA of patients contains This that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>inactivation of the MEF2C gene DNA of patients contains This that led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This leading to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This leading to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This that has led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This that has led to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This that led to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>inactivation of the MEF2C gene basic pair G:C is also the strongest determinant in This leading to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>inactivation of the MEF2C gene basic pair G:C is also the strongest determinant in This that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 (figuration 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic (figuration 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>inactivation of the MEF2C gene data suggests that This can lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>inactivation of the MEF2C gene data suggests that This led to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>inactivation of the MEF2C gene data suggests that This led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>inactivation of the MEF2C gene data suggests that This was able to lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>inactivation of the MEF2C gene is able to lead to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 (figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>inactivation of the MEF2C gene is able to lead to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>inactivation of the MEF2C gene is able to lead to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos (figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>inactivation of the MEF2C gene is leading to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>inactivation of the MEF2C gene led morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day (figuration 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos (figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 (figuration 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>inactivation of the MEF2C gene may lead to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>inactivation of the MEF2C gene may lead to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>inactivation of the MEF2C gene patient DNA contains This that can lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>inactivation of the MEF2C gene was caused by This leading to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>inactivation of the MEF2C gene was caused by This leading to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>inactivation of the MEF2C gene was caused by This leads to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>inactivation of the MEF2C gene was caused by This that can lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>inactivation of the MEF2C gene was caused by This that leads to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>inactivation of the MEF2C gene was caused by This that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="564">
                    <text>inactivation of the MEF2C gene was caused by This that led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="565">
                    <text>inactivation of the MEF2C gene was caused by This that may lead to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="566">
                    <text>inactivation of the MEF2C gene was caused by This that may lead to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="567">
                    <text>inactivation of the MEF2C gene was caused by This which has led to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="568">
                    <text>inactivation of the MEF2C gene was caused by This which leading to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="569">
                    <text>inactivation of the MEF2C gene was caused by This which led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="570">
                    <text>inactivation of the MEF2C gene will lead to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="571">
                    <text>inactivation of the MEF2C gene will lead to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="572">
                    <text>inactivation of the MEF2C gene will lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="573">
                    <text>inactivation of the MEF2C gene will lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="574">
                    <text>ligation of the second to the fourth exon was led by a point mutation at the splicing 5 site of the third intron.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="575">
                    <text>loss of the TreR function base pair G:C is also the strongest determinant in This that led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="576">
                    <text>loss of the TreR function can lead to derepression of the treB, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="577">
                    <text>loss of the TreR function data suggests that This will lead to derepression of treB that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="578">
                    <text>loss of the TreR function is able to lead derepression of treB (picture 3A).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="579">
                    <text>loss of the TreR function is leading to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="580">
                    <text>loss of the TreR function leads to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="581">
                    <text>loss of the TreR function led to derepression of the treB (figure 3A).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="582">
                    <text>loss of the TreR function was caused by This that can lead to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="583">
                    <text>loss of the TreR function was caused by This which has led to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="584">
                    <text>loss of the TreR function will lead to derepression of the treB coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="585">
                    <text>loss of the TreR function will lead to derepression of treB coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="586">
                    <text>morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo was led to inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="587">
                    <text>morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day is led by inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="588">
                    <text>morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day was led to inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="589">
                    <text>morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos was led to inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="590">
                    <text>morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 is led to inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="591">
                    <text>morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 was led by inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="592">
                    <text>shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations is led by two frame shifts and a mutation of the splice site.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="593">
                    <text>the 5-end mutation of the intron 5 DNA of patients contains This that led to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="594">
                    <text>the 5-end mutation of the intron 5 basic pair G:C is also the strongest determinant in This leading to abnormal portion in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="595">
                    <text>the 5-end mutation of the intron 5 data suggests that This was able to lead to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="596">
                    <text>the 5-end mutation of the intron 5 leads to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="597">
                    <text>the 5-end mutation of the intron 5 led to abnormal portion in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="598">
                    <text>the 5-end mutation of the intron 5 led to abnormal portion in exon 5 and exon 6, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="599">
                    <text>the 5-end mutation of the intron 5 patient DNA contains This that can lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="600">
                    <text>the 5-end mutation of the intron 5 was caused by This that may lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="601">
                    <text>the abnormal splice in exon 5 and exon 6 was led by the mutation of the splice at 5 ends of the intron 5.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="602">
                    <text>the different amino acid terminals basic pair G:C is also the strongest determinant in This leading to the orientation of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="603">
                    <text>the different amino acid terminals basic pair G:C is also the strongest determinant in This that led to the orientation of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="604">
                    <text>the different amino acid terminals can lead to the orientation of individual VDAC isoforms to different cellular compartments (figuration 3A).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="605">
                    <text>the different amino acid terminals leading to the orientation of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="606">
                    <text>the different amino acid terminals leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="607">
                    <text>the different amino acid terminals may lead to the orientation of individual VDAC isoforms to different cellular compartments (figure 3A).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="608">
                    <text>the different amino terminals data suggests that This can lead to the orientation of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="609">
                    <text>the different amino terminals data suggests that This led to the orientation of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="610">
                    <text>the different amino terminals is leading to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="611">
                    <text>the different amino terminals leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="612">
                    <text>the different amino terminals led to the orientation of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="613">
                    <text>the different amino terminals led to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="614">
                    <text>the different amino terminals may lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="615">
                    <text>the different amino terminals was caused by This leading to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="616">
                    <text>the different amino terminals was caused by This leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="617">
                    <text>the direction of individual VDAC isoforms to different cellular compartments was led to the distinct termini amino acid.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="618">
                    <text>the distinct termini amino acid base pair G:C is also the strongest determinant in This leads to the direction of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="619">
                    <text>the distinct termini amino acid can lead to the direction of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="620">
                    <text>the distinct termini amino acid is able to lead the direction of individual VDAC isoforms to different cellular compartments (picture 3A).</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="621">
                    <text>the distinct termini amino acid is able to lead to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="622">
                    <text>the distinct termini amino acid is leading to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="623">
                    <text>the distinct termini amino acid leading to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="624">
                    <text>the distinct termini amino acid was caused by This that led to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="625">
                    <text>the distinct termini amino acid, in turn, is leading to the direction of individual VDAC isoforms to different cellular compartments regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="626">
                    <text>the mutation of the splice at 5 ends of the intron 5 basic pair G:C is also the strongest determinant in This leading to the abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="627">
                    <text>the mutation of the splice at 5 ends of the intron 5 basic pair G:C is also the strongest determinant in This leading to the splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="628">
                    <text>the mutation of the splice at 5 ends of the intron 5 can lead to the splice in exon 5 and exon 6 (figuration 3A).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="629">
                    <text>the mutation of the splice at 5 ends of the intron 5 can lead to the splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="630">
                    <text>the mutation of the splice at 5 ends of the intron 5 data suggests that This will lead to the splice in exon 5 and exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="631">
                    <text>the mutation of the splice at 5 ends of the intron 5 has led in the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="632">
                    <text>the mutation of the splice at 5 ends of the intron 5 is able to lead to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="633">
                    <text>the mutation of the splice at 5 ends of the intron 5 is able to lead to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="634">
                    <text>the mutation of the splice at 5 ends of the intron 5 led to the abnormal splice in exon 5 and exon 6 (figure 3A).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="635">
                    <text>the mutation of the splice at 5 ends of the intron 5 may lead to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="636">
                    <text>the mutation of the splice at 5 ends of the intron 5 was caused by This that can lead to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="637">
                    <text>the mutation of the splice at 5 ends of the intron 5 was caused by This that can lead to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="638">
                    <text>the mutation of the splice at 5 ends of the intron 5 was caused by This which led to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="639">
                    <text>the mutation of the splice at 5 ends of the intron 5 will lead to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="640">
                    <text>the orientation of individual VDAC isoforms to different cellular compartments was led by the different amino acid terminals.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="641">
                    <text>this mutation at 5 ends of the intron 5 base pair G:C is also the strongest determinant in This that led to abnormal portion in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="642">
                    <text>this mutation at 5 ends of the intron 5 data suggests that This was able to lead to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="643">
                    <text>this mutation at 5 ends of the intron 5 has led in abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="644">
                    <text>this mutation at 5 ends of the intron 5 is able to lead abnormal portion in exon 5 and exon 6 (picture 3A).</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="645">
                    <text>this mutation at 5 ends of the intron 5 leads to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="646">
                    <text>this mutation at 5 ends of the intron 5 led to abnormal portion in exon 5 and exon 6, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="647">
                    <text>this mutation at 5 ends of the intron 5 was caused by This leads to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="648">
                    <text>this mutation at 5 ends of the intron 5 was caused by This that can lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="649">
                    <text>this mutation at 5 ends of the intron 5 was caused by This which has led to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="650">
                    <text>this mutation at 5 ends of the intron 5 will lead to abnormal portion in exon 5 and exon 6 coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="651">
                    <text>truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations was led by two frameshifts and a splice site mutation.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="652">
                    <text>two frame shifts and a mutation of the splice site base pair G:C is also the strongest determinant in This leads to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="653">
                    <text>two frame shifts and a mutation of the splice site base pair G:C is also the strongest determinant in This that led to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="654">
                    <text>two frame shifts and a mutation of the splice site can lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="655">
                    <text>two frame shifts and a mutation of the splice site data suggests that This led to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="656">
                    <text>two frame shifts and a mutation of the splice site led to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations (figuration 3A).</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="657">
                    <text>two frame shifts and a mutation of the splice site may lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations (figure 3A).</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="658">
                    <text>two frame shifts and a mutation of the splice site may lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="659">
                    <text>two frame shifts and a mutation of the splice site was caused by This that led to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="660">
                    <text>two frameshifts and a splice site mutation can lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations (figuration 3A).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="661">
                    <text>two frameshifts and a splice site mutation led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations (figuration 3A).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="662">
                    <text>two frameshifts and a splice site mutation led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations (figure 3A).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="663">
                    <text>two frameshifts and a splice site mutation was caused by This leading to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="664">
                    <text>two frameshifts and a splice site mutation was caused by This that led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="665">
                    <text>two frameshifts and a splice site mutation will lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
